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1 General introduction 
 
1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) constitute the largest known gene superfamily (≈ 2 %) 
of the human genome with up to approximately 800 members. Over half of these 
representatives are olfactory, leaving ≈ 380 unique functional nonolfactory/nonsensory 
GPCRs of which about only 40 are known as targets of modern drugs. Nevertheless, up to 
30 % of all marketed prescription drugs act on GPCRs (Jacoby et al., 2006; Lagerström and 
Schiöth, 2008). Thus, G protein-coupled receptors offer an interesting field with high 
potential for drug discovery. 
Though, the physiological agonists are extremely versatile, ranging from light, ions, amines, 
peptides to proteins (Bockaert and Pin, 1999), GPCRs can be phylogenetically divided into 
five main families termed glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin 
(Fredriksson et al., 2003). The common structural features of the G protein-coupled receptor 
superfamily are seven membrane-spanning helices connected by three alternating intracellular 
and extracellular loops and flanked by an extracellular N-terminus and an intracellular C-
terminus, respectively. Due to the high abundance in retina the bovine rhodopsin was the first 
mammalian GPCR to be crystallized by Palczewski in 2000, providing the first insight into 
the three-dimensional architecture of a G protein-coupled receptor (Palczewski et al., 2000). 
Further crystal structures have been resolved recently for the human β2-adrenoceptor (hβ2AR) 
(Rasmussen et al., 2007; Rosenbaum et al., 2007), the turkey β1AR (Warne et al., 2008) and 
the human adenosine 2A receptor (Jaakola et al., 2008), which was only possible by diverse 
receptor modifications like truncation, use of an antibody or construction of a receptor/T4-
lysozyme fusion protein as stabilizing elements in combination with receptor bound inverse 
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agonists or antagonists. These efforts were amongst others performed to elucidate receptor 
conformation upon activation by ligand binding and coupling to heterotrimeric G proteins, the 
mediators of intracellular effects (cf. section 1.3). However, in contrast to their original 
denomination, GPCRs do not only signal via heterotrimeric G proteins, but interaction with β-
arrestin after receptor phosphorylation is part of the major signaling process (Violin and 
Lefkowitz, 2007; Rajagopal et al., 2010), which comprises e.g. regulation of kinases - like 
MAPKs, SRC or AKT – and of the receptor itself by desensitization and internalization. 
Therefore, GPCRs lately are also named seven transmembrane receptors (7TMRs). The 
present work focuses on GPCR signaling via heterotrimeric G proteins. A detailed illustration 
of the G protein activation/deactivation cycle is shown in section 1.3. 
 
1.2 The neuropeptide Y (NPY) multiligand/multireceptor system 
1.2.1 The neuropeptide Y family of peptides 
Neuropeptide Y (NPY) represents together with peptide YY (PYY) and the pancreatic 
polypeptide (PP) a ligand family of neuroendocrine hormones, consisting of 36 amino acids 
each with C-terminal amidation (Fig. 1.1). NPY is one of the most abundant neuropeptides in 
the brain (Gray and Morley, 1986), additionally it is also expressed in the peripheral nervous 
system and plays an important role in the regulation of many physiological processes, such as 
food intake, thermogenesis, mood, memory, blood pressure and reproduction (Berglund et al., 
2003). At the same time NPY is also extremely well conserved among species (Larhammar, 
1996). By contrast, PYY shows greater variability, and PP is the most rapidly evolving 
member of the NPY peptide family with only 50 % identity within mammals. PYY and PP 
are hormones that are released in the gastrointestinal tract in response to meals to regulate 
pancreatic and gastric secretion (Tatemoto, 1982; Hazelwood, 1993). PYY is additionally 
present in neurons (Ekblad and Sundler, 2002). Each of the NPY receptors shows its 
individual ligand binding profile for the members of the NPY family of peptides (Table 1.1). 
 
  1         10           20            30 
hNPY  YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
hPYY  YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
hPP  APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
Fig. 1.1: Alignment of the human NPY, PYY and PP amino acid sequence; Constant positions in all species for 
the three peptides are underlined. The seven constant residues within the NPY-family are indicated (boxed). 
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1.2.2 NPY receptors 
NPY receptors belong to the rhodopsin like GPCR superfamily and have a common main 
signaling pathway via Gi/o proteins (Michel et al., 1998). Subtypes in humans comprise the 
Y1, Y2, Y4, Y5 and y6, with the y6 being non-functional because of a frameshift mutation 
(single base deletion) in the third intracellular loop leading to a truncated receptor protein 
after the 6th transmembrane region (Rose et al., 1997). The average sequence homology 
between the subtypes is relatively low (27-31 %). NPY receptors play a role in a plethora of 
physiological processes. Some examples of current NPY investigation fields are their 
implication in depression (Painsipp et al., 2009a; Painsipp et al., 2009b), alcohol dependence 
(Thorsell, 2007; Wetherill et al., 2008) or pain modulation (Gibbs and Hargreaves, 2008). 
Besides the pharmacological aspect as a target the Y1 receptor e.g. is also regarded as a tumor 
marker in breast cancer as it is overexpressed in malignant tissues (Amlal et al., 2006). 
However, the most prominent effect mediated by the NPY multiligand/multireceptor system 
still remains its involvement in regulating energy homeostasis. For example, Y1 or Y5 
receptor selective agonists stimulate feeding (Gerald et al., 1996; Mullins et al., 2001; Henry 
et al., 2005) and antagonists produce anti-obesity effects. In contrast, Y2 or Y4 receptor 
selective agonists show inhibition of food intake (Batterham et al., 2002; Asakawa et al., 
2003), though these findings were controversially discussed (Tschöp et al., 2004). As obesity 
and resulting co-morbidities are increasing health problems there has been a special interest in 
NPY receptor ligands (cf. section 1.2.3). In Table 1.1 an overview of the most important 
properties of NPY receptors is given (for a survey of Y receptor antagonists see section 1.2.3.) 
 
Table 1.1: Overview of NPY receptors adapted from (Merten and Beck-Sickinger, 2006) 
 
Y1R 
 
Expression pattern 
 
 
Signal transduction 
 
Physiological functions 
 
 
Ligand binding profile 
(agonists) 
 
Selective agonists 
 
 
 
 
Cerebral cortex, vascular smooth muscle cells, colon, human 
adipocytes 
 
Gi/o → cAMP↓; [Ca2+]↑ 
 
Analgesia, anxiolysis, circadian rhythm regulation, endocrine 
regulation, increase feeding, sedative, vasoconstriction 
 
NPY ≈ PYY ≈ [Leu31,Pro34]NPY > NPY2-36 ≈ NPY3-36 ≥ PP ≈ 
NPY13-36 
 
[Phe7,Pro34]NPY; [Leu31,Pro34]NPY/PYY; [Arg6,Pro34]NPY 
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Y2R 
 
Expression pattern 
 
Signal transduction 
 
Physiological functions 
 
 
Ligand binding profile 
(agonists) 
 
Selective agonists 
 
 
 
 
Nerve fibers, hippocampus, intestine, blood vessels 
 
Gi/o → cAMP↓; [Ca2+]↑ 
 
Angiogenesis, anxiogenesis, enhanced memory, decreased 
neurotransmitter secretion, decrease feeding, anticonvulsant 
 
PYY > PYY3-36 ≈ NPY3-36 ≈ NPY2-36 ≈ NPY13-36 >> 
[Leu31,Pro34]NPY 
 
NPY3-36; NPY13-36; [Ahx5-24]NPY 
 
 
Y4R 
 
Expression pattern 
 
 
Signal transduction 
 
Physiological functions 
 
 
Ligand binding profile 
(agonists) 
 
Selective agonists 
 
 
 
 
Hypothalamus, skeletal muscle, thyroid gland, stomach, small 
intestine, colon 
 
Gi/o → cAMP↓; [Ca2+]↑ 
 
Pancreatic secretion, gall bladder contraction, LH secretion, 
decrease feeding 
 
PP ≥ GW1229 > PYY ≥ NPY > NPY2-36 
 
 
PP; GW1229 
 
 
Y5R 
 
Expression pattern 
 
 
Signal transduction 
 
Physiological functions 
 
 
Ligand binding profile 
(agonists) 
 
Selective agonists 
 
 
 
 
Hypothalamus, cerebral cortex, intestine, ovary, spleen, 
pancreas, skeletal muscle 
 
Gi/o → cAMP↓; [Ca2+]↑ 
 
Circadian rhythm regulation, increase feeding, anticonvulsant, 
reproduction 
 
NPY ≈ PYY ≈ NPY2-36 ≈ [Leu31,Pro34]NPY > hPP > 
[D-Trp32]NPY > NPY13-36 > rPP 
 
[Ala31,Aib32]NPY; [Leu31,Pro34]NPY; [D-Trp34]NPY 
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1.2.3 NPY receptor ligands 
Starting from the endogenous ligands, NPY, PYY and PP, structure-affinity/activity 
relationships have been intensely studied by peptide modifications such as amino acid 
replacements, truncations, cyclizations or building chimera. Thereby, selective peptidergic 
agonists (listed in Table 1.1) have been widely accepted as reference compounds for the 
characterization of NPY receptors (Beck-Sickinger et al., 1992; Cabrele and Beck-Sickinger, 
2000; Cabrele et al., 2000). Likewise, essential structures from the endogenous ligands were 
identified for the binding to each receptor. Thus, the small-molecule antagonist reported for 
the Y1R, BIBP 3226 (Rudolf et al., 1994) (Fig. 1.2), is considered a mimic of the C-terminus, 
i.e. Arg35 and Tyr36 in NPY (Sautel et al., 1996). The first non-peptidic antagonist was HE- 
90481 (Michel and Motulsky, 1990). Likewise, BIIE 0246 (Doods et al., 1999; Dumont et al., 
2000) and CGP 71683A (Criscione et al., 1998) (Fig. 1.3) represented the first selective and 
potent antagonists for the Y2R and the Y5R, respectively. In the following, an overview of the 
development of Y receptor ligands of the last five years is given. As reviewed by Sato et al. 
(2009b), the major motivation to design new compounds for neuropeptide Y receptors was the 
treatment of obesity. Due to the lack of oral availability and inability to penetrate across the 
blood brain barrier NPY receptors could not be easily addressed in vivo with the classical 
substances. However these have been useful pharmacological tools for the characterization of 
YRs. 
Fig. 1.2 shows a selection of developed novel potent and selective Y1 receptor antagonists, all 
of which show promising results in the inhibition of feeding and the reduction of body weight 
in animal models, however only if applied systemically, i.e. intracerebroventricularly, 
intravenously or intraperitoneally (i.c.v., i.v. or i.p.). In order to advance into clinical trial, 
there is still a need for substances with suitable pharmacokinetic profiles and physicochemical 
properties. 
Beside the aim to treat obesity several compounds have been developed as pharmacological 
tools. For example, Keller et al. designed a tritium labeled NG-propionylargininamide ([3H]-
UR-MK114) that is a BIBP 3226 derivative (Keller et al., 2008). Moreover, there have been 
reports on agonists with peptidic structures for PET or SPECT imaging of breast cancer 
(Guerin et al., 2010; Khan et al., 2010) and a carboxyfluorescein labeled small peptide 
derivative for tumour diagnostics and therapy (Zwanziger et al., 2009). 
6 Chapter 1 
 
Fig. 1.2: Selection of non-peptidic Y1 antagonist;  a(Rudolf et al., 1994), b(Wieland et al., 1998), c(Kanatani et 
al., 2001), d(Leslie et al., 2007), e(Antal-Zimanyi et al., 2008), f(Kameda et al., 2009) 
 
Several novel compounds different in structure from the peptidomimetic BIIE 0246 have been 
designed for the Y2 receptor (Fig. 1.3). Here the situation is similar as for the Y1R, namely the 
development of many potent and selective substances has been successful (for review see 
(Sato et al., 2009b). These compounds were demonstrated to penetrate into the brain 
(Brothers et al., 2010) when administered i.p. or subcutaneuosly (s.c.) Apart from the 
synthesis of small molecules the attempt has been pursued to conjugate peptidic Y2R agonists 
(based on the C-terminus of PYY) with polyethylene glycol (20 kDa) to achieve a higher 
stability and to modify the amino acid sequence for higher selectivity. Indeed, the substances 
showed reduction of food intake and body weight (DeCarr et al., 2007; Lumb et al., 2007; 
Ortiz et al., 2007). Obinepitide, a Y2/Y4 dual peptide agonist is reported to be in clinical trial 
(Sato et al., 2009b). 
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Fig. 1.3: Selection of non-peptidic Y2 antagonists; a(Doods et al., 1999), b(Bonaventure et al., 2004), c(Brothers 
et al., 2010), d(Shoblock et al., 2010) 
 
For the Y4 receptor only UR-AK49, a weak antagonist, has been reported up to date (Ziemek 
et al., 2007) (Fig. 1.4). In Table 1.1 GW1229, based on the C-terminus of NPY, is mentioned 
as a selective and potent Y4R agonist (Parker et al., 1998; Schober et al., 1998), although this 
compound is also active at the Y1R as an antagonist. Furthermore, recent studies are focusing 
on peptidergic agonists as the Y4R is known to mediate satiety via the release of PP in 
response to meals. For example, Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 - a peptide dimer based 
on NPY32-36 - has been reported to be a selective and highly potent Y4 agonist, which 
inhibited food intake in mice after i.p. application (Balasubramaniam et al., 2006). As already 
mentioned for the Y2, the strategy to address Y2 and Y4 receptors at the same time with 
selective peptidergic agonists is pursued (Balasubramaniam et al., 2007). 
 
Fig. 1.4: UR-AK49, an acylguanidine with moderate Y4 antagonistic activity; aInhibition of hPP induced 
luminescence in CHO cells expressing the hY4R, the chimeric G protein Gqi5 and mitochondrially targeted 
apoaequorin. 
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The first non-peptidic Y5 antagonist reported was CGP 71683A (Criscione et al., 1998), 
whereas MK-0557 (Erondu et al., 2006) was the first substance to be applied in clinical trial. 
As MK-0557 was well tolerated and showed small, but statistically significant reduction in 
body weight, several new compounds were designed (Fig. 1.5), (Ando et al., 2009; Haga et 
al., 2009; Sato et al., 2009a) with promising pharmacological and pharmacokinetic properties 
so that proof-of-concept studies in humans are planned. Due to its expression in the limbic 
system, the Y5R was hypothesized to modulate stress sensitivity. Indeed, Lu AA33810 was 
shown to exert anxiolytic- and antidepressant-like effects in rats (Walker et al., 2009). 
 
Fig. 1.5: Selection of Y5R antagonists ; a(Criscione et al., 1998), b(Erondu et al., 2006), c(Ando et al., 2009), 
d(Sato et al., 2009a), e(Walker et al., 2009) 
 
1.3 Development of novel functional assays for NPY receptors 
Principally, for the pharmacological characterization of GPCR ligands, such as the substances 
presented in the previous section, in addition to binding data, the determination of the quality 
of action, agonistic potency or antagonistic activity is a must. There are numerous methods to 
determine potency and efficacy of ligands at the GPCR of interest, each of which has its 
specific applications, advantages and disadvantages. Therefore, a maximum of information on 
a given GPCR can only be obtained by combining complementary approaches.  
For an overview of existing functional assays for NPY receptors the reader is referred to the 
introductory sections of chapters 4 to 6. This work aims at the development of new assay 
types presented in the current section exploiting GPCR signaling via various heterotrimeric G 
proteins. 
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As already mentioned (section 1.1), one of the prevailing signaling pathways of 7TMRs is 
coupling to heterotrimeric G proteins. Upon agonist binding a conformational change of the 
receptor takes place leading to association with a free inactive G protein consisting of a Gα-
subunit and a Gβγ heterodimer, located on the cytosolic side of the membrane. Subsequently, 
Gα-bound GDP is released and replaced by GTP, which causes the dissociation of the ternary 
complex into the GPCR, the GTP-bound Gα-subunit and the Gβγ-dimer. The G protein 
subunits each activate effector proteins until the intrinsic GTPase activity of Gα cleaves the 
nucleotide into GDP and inorganic phosphate (Pi). Termination of the cycle is completed by 
the association of GDP-bound Gα with the Gβγ-dimer. The inactive G protein heterotrimer is 
available for another round of activation (Fig. 1.6). 
 
There are four classes of G proteins with respect to the homology of their Gα sequences: Gs, 
Gi/o, Gq/11 and G12/13 (Cabrera-Vera et al., 2003; Milligan and Kostenis, 2006). Gs proteins 
activate adenylyl cyclase (AC), which results in the formation of 3´,5´-adenosine mono-
phosphate (cAMP). Members of the Gi/o class inhibit AC, while Gq/11 activate 
phospholipase Cβ (PLCβ), that catalyzes the formation of inositol-1,4,5-triphosphate (IP3) 
and 1,2-diacylglycerol (DAG). G12/13 proteins interact with guanine nucleotide exchange 
factors. The modulation of the mentioned second messengers leads to diverse downstream 
cellular signals, e.g. cAMP activates protein kinase A (PKA) resulting in the phosphorylation 
of various substrate proteins. Furthermore, exchange proteins directly activated by cAMP 
(Epac) as well as cAMP-gated ion channels are regulated. The inhibition of cAMP formation 
prevents these effects. Elevated IP3 levels result in the release of intracellular calcium (Ca2+) 
Fig. 1.6: G protein activation/ 
deactivation cycle after GPCR 
stimulation by an agonist; Adapted 
from (Seifert and Wieland, 2005) 
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from the endoplasmic reticulum (ER), while DAG stimulates protein kinase C (PKC), which 
in turn stimulates various intracellular proteins by phosphorylation. Additionally, activated 
Gβγ-dimers can also trigger cellular effects, for instance, by interacting with AC, PLCβ or 
certain ion channels. 
Gα-subunits as well as Gβγ-heterodimers are anchored to the cell membrane by lipidation of 
their N-termini. The interaction of Gα with a GPCR is defined by the amino acid sequence of 
its C-terminus, which is recognized by the receptor. 
A large and diverse family of proteins – the regulators of G protein signaling (RGS) – has its 
part in the G protein cycle by accelerating the GTPase activity of the Gα-subunit (Ross and 
Wilkie, 2000; Willars, 2006) by stabilization of the transition state of GTP cleavage. Thus, 
RGS proteins function as negative regulators of G protein signaling.  
 
1.3.1 FRET based cAMP assay for the human NPY Y1 receptor 
In case of the NPY receptors, coupling to Gi/o proteins, the inhibition of cAMP formation has 
to be measured to determine receptor activation. Therefore, pre-stimulation with e.g. 
forskolin, a direct activator of adenylyl cyclase, is required to see an effect. Classical assay 
formats for YRs are based, for example, on measuring cAMP radioimmunologically or 
spectroscopically after enzymatic conversion of the second messenger to NADPH. To avoid 
such hazardous and laborious approaches in monitoring cAMP levels, several sensors have 
been developed from structures of known interaction partners of the second messenger, which 
are, e.g., exchange protein, directly activated by cAMP 1 (Epac1) and Epac2 (de Rooij et al., 
1998; Bos, 2003). Such proteins contain a catalytic domain regulated by a cAMP binding site. 
Upon binding of the second messenger, the conformation of Epac is changed, releasing the 
catalytic part. Because of this unfolding of the protein (the termini are supposed to move 
away from each other) the cyan and yellow fluorescent proteins (CFP and YFP) have been 
fused to the ends and cAMP has been measured by means of fluorescence resonance energy 
transfer (FRET) (Ponsioen et al., 2004). For FRET to take place, the applied fluorophores 
have to overlap in their emission and absorption spectra, as shown for CFP and YFP as an 
example in Fig. 1.7 A. Moreover, they have to be in close proximity to each other, i.e. 
1-10 nm, which means that in case of CFP-Epac-YFP, the FRET efficiency decreases upon 
cAMP formation. A further development, devoid of the catalytic domain of Epac, is the Epac 
cAMP sensor (Epac-camps) (Nikolaev et al., 2004; Nikolaev et al., 2005), which contains a 
cAMP binding site flanked by CFP and YFP (Fig. 1.7 B). This protein was used in an 
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approach to establish a FRET based assay in SK-N-MC cells endogenously expressing the 
hY1R (chapter 3). 
 
1.3.2 Fluorescence and luminescence based calcium assays for the human 
NPY Y5 receptor 
Conklin et al (Conklin et al., 1993) have shown that the G protein specificity of a GPCR 
depends on its C-terminal amino acid sequence. Subsequently, several G protein chimera 
were constructed, e.g., consisting of Gαq with the last amino acids replaced by those of Gαi2 
(Conklin et al., 1996), thus being able to re-direct receptor signaling to the PLC pathway. 
Such chimeric G proteins have already been successfully applied in high throughput screening 
(HTS) at Gi/o coupling receptors (Coward et al., 1999; Dautzenberg, 2005; Dautzenberg et al., 
2005). Ca2+ chelating dyes such as fluo-4 or the ratiometric fura-2 are used to measure the 
intracellular Ca2+ mobilization in flow cytometric or spectrofluorimetric assays as already 
established, e.g., for the hY2 and the hY4 receptors, stably co-expressed with Gαqi5 in CHO 
cells (Ziemek et al., 2006; Ziemek et al., 2007). Because such fluorescence based assays 
suffer from dye leakage from the cells, which results in decreased signal-to-noise ratios 
during experiments, another approach based on luminescence with the photoprotein aequorin 
targeted to the mitochondria (see below) is favorable (Ziemek et al., 2006; Ziemek et al., 
2007). Aequorin is a luciferase, which is reconstituted as a holoprotein with its chromophore 
cofactor coelenterazine (a luciferin). Upon binding of Ca2+, coelenterazine is oxidized to 
coelenteramide, and CO2, and luminescence occurs (λmax = 470 nm) (Shimomura and 
Johnson, 1978; Jones et al., 1999). The advantages of aequorin as an intracellular calcium 
indicator are its high sensitivity, low background, as well as absence of toxicity and its large 
linear dynamic range (Dupriez et al., 2002). For functional GPCR assays cytoplasmically 
expressed and mitochondrially targeted aequorin (cytAEQ and mtAEQ) have been applied, 
A B
Fig. 1.7: Absorbance and emission spectra of CFP and YFP (A) and the principle of Epac-camps (B) 
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both giving the same functional data (Stables et al., 1997; Stables et al., 2000), whereas 
substantially stronger luminescence was obtained with mtAEQ. 
 
1.3.3 Steady-state GTPase assay for the human NPY Y2 and Y4 receptors 
The steady-state GTPase assay aims at directly measuring receptor activation, which 
subsequently results in the activation of the G protein cycle and the cleavage of [γ-32P]GTP. 
This is favorable for GPCRs coupling to Gi/o proteins, such as the NPY receptors, as no pre-
stimulation is necessary.  
For such assays membranes containing the respective GPCR, appropriate G proteins are 
required and in some cases the coexpression of RGS proteins turned out to be useful. To 
generate such membranes, the baculovirus/Sf9 cell expression system is used, which is well 
established for many GPCRs (Massotte, 2003; Aloia et al., 2009). The Sf9 cell line is derived 
from Spodoptera frugiperda ovarian tissue and can be infected by the highly species-specific 
baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV), which was used for 
expression purposes. Recombinant baculovirus containing receptor cDNA had to be 
generated. Because the genome of AcNPV is too large to easily insert foreign genes, a transfer 
vector (pVL1392) is used. The foreign gene is inserted into the vector in such a way that its 
expression is controlled by the strong late phase polyhedrin promoter. Polyhedrin, the matrix 
protein in which virus particles are embedded, can be replaced by the cDNA of interest. Upon 
co-transfection into Sf9 cells (Fig.1.8), the transfer vector and the linearized baculovirus DNA 
undergo homologous recombination, yielding viable recombinant baculovirus. 
 
Fig. 1.8: Generation of 
recombinant hYxR-ba-
culoviruses and protein 
expression 
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By the infection of Sf9 cells with such viruses high GPCR or G protein expression levels can 
be achieved (Seifert et al., 1998; Massotte, 2003; Schneider et al., 2009). Co-infection with 
up to four baculoviruses, thereby combining the receptor of interest with diverse Gα-, Gβγ-
subunits and RGS proteins, is tolerated by the cells (Kleemann et al., 2008). Thus, for 
example G protein selectivity of the GPCR of interest can be studied.  
From functional experiments and immunoblot analyses it can be concluded that Sf9 cells do 
not express any constitutively active GPCRs, i.e. receptors, that isomerize to the activated 
form in the absence of agonists, and that signaling of mammalian GPCRs via endogenous G 
protein is limited (Quehenberger et al., 1992; Wenzel-Seifert et al., 1998; Brys et al., 2000; 
Seifert et al., 2003). This was considered as an excellent starting point for the establishment 
of functional assays with high signal-to-noise ratios for the molecular pharmacological 
investigation of NPY receptor ligands and for studying constitutive receptor activity. 
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2 Scope and Objectives 
 
During the last decades obesity and its co-morbidities like hypertension, diabetes type II, 
coronary heart disease, have emerged as severe diseases in the modern world, causing 
immense expenses in a country’s health systems. With the NPY receptor family playing a 
major role in appetite regulation and energy expenditure, ongoing efforts are focusing on the 
development of potent and orally available ligands of the Y receptors to solve the 
aforementioned problem, with more or less promising results (Sato et al., 2009). To date, the 
Y2R and Y5R are the only members of the NPY receptor family, at which small molecular 
antagonists fulfill, as outlined above, the demands concerning pharmacodynamic and 
pharmacokinetic properties (see section 1.3). Appropriate Y4R antagonists are unknown so 
far. Regarding the wide field of additional physiological effects, e.g. regulation of mood, 
cognition, pain, circadian rhythm and angiogenesis, with high potential for drug discovery, 
sensitive and reliable methods for both screening and detailed molecular pharmacological 
studies are needed to accelerate ongoing investigations. 
Due to the common signaling pathway of NPY receptors, namely the coupling to Gi/o proteins, 
classical ligand screening assays are based on the radioimmuno detection of cAMP formation 
in cells (CHO, HEK293), expressing the GPCR of interest. Thereby, the stimulation of 
adenylyl cyclase by forskolin is needed to reveal inhibitory effects of Y receptor agonists. In 
the present work a further development of this assay format and more straightforward ways of 
determining ligand potencies and efficacies were pursued: 
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− With the application of Epac-camps (Nikolaev et al., 2004), a promising cAMP 
sensor, a sophisticated in vitro assay based on fluorescence resonance energy transfer 
(FRET), should be developed in SK-N-MC cells, endogenously expressing the hY1R. 
Epac is an engineered protein consisting of a cAMP binding site flanked by enhanced 
cyan fluorescent protein (CFP) and enhanced yellow fluorescent protein (YFP). 
Increased cAMP concentrations in the cell due to extracellular stimuli, should lead to 
the binding of the second messenger and subsequently to a change in its conformation 
moving the fluorophores apart and thereby eliminating FRET. The change in donor 
and acceptor fluorescence should be measurable depending on the concentration of 
intracellular cAMP. This concept would enable the avoidance of radioactivity and 
even live cell imaging by confocal laser scanning microscopy (CLSM). As a starting 
point, single cell imaging should prove the functionality of Epac-camps as a cAMP 
sensor. However, the final goal was to establish an HTS assay system by means of 
fluorescence spectroscopy using a fluorescence plate reader (96-well format). 
− By analogy to the well established luminescence based aequorin assay for the hY2R 
and the hY4R developed in our work group (Ziemek et al., 2006; Ziemek et al., 2007), 
HEC-1B-hY5 cells should be stably transfected with the genes encoding chimeric 
G proteins (Conklin et al., 1996) and, subsequently after assuring the Ca2+ signal, with 
the gene encoding the fluorescent protein aequorin, targeted to the mitochondria. The 
above mentioned assay format is desirable because of the direct readout (increasing 
intracellular calcium) upon receptor stimulation and a usually very high signal-to-
noise ratio. The HEC-1B-hY5 cell line, previously established in our work group 
(Moser et al., 2000), was considered suitable for this purpose. The chimeric G protein, 
Gαqi5, had to be modified by PCR to Gαqi9 to potentially increase receptor coupling. 
After stable transfection of the cells, initially a spectrofluorimetric and a flow 
cytometric fluorescence based calcium assay should be established and modified to 
allow luminescence based aequorin assays. 
− Finally, a steady-state GTPase assay, which is well established for many other GPCRs 
(Massotte, 2003; Wieland and Seifert, 2005), should be developed for the hY2R and 
the hY4R, using the baculovirus/Sf9 system, which is especially suited for Gi/o coupled 
receptors, because e.g. GTP hydrolysis following receptor activation is measured. In 
such a system there is no need of pre-stimulation by forskolin. Due to the proximal 
readout, amplification steps that would complicate stoichiometry are not included. 
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This ensures that e.g. partial agonists can be discriminated from full agonists. 
Furthermore, with a steady-state GTPase assay constitutive receptor activity can be 
identified, and if so, an appropriate system for the screening of inverse agonists is 
available. In the baculovirus/Sf9 system GPCRs, G proteins and regulators of 
G protein signaling (RGS) proteins can be deliberately combined and the engineered 
Sf9 membranes can be characterized biochemically, e.g. with respect to expression 
levels and ratios of relevant proteins by immunoblotting, and pharmacologically using 
standard ligands. Finally, investigations on the impact of receptor N-glycosylation are 
feasible by culturing infected insect cells in the presence of the GlcNAc-1P-
transferase, tunicamycin. 
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3 Towards a FRET based functional cAMP assay for the 
human NPY Y1 receptor in SK-N-MC cells 
 
3.1 Introduction 
The first fluorescent indicator for cAMP used in real-time measurements in live cells was a 
cAMP-dependent protein kinase in which the catalytic (C) and regulatory (R) subunits were 
each labeled with fluorescein or rhodamine, respectively, enabling fluorescence resonance 
energy transfer (FRET) in the holoenzyme complex R2C2 (Adams et al., 1991). Binding of 
cAMP to the R subunit results in the dissociation of the C subunits, thereby eliminating 
energy transfer. This modified protein kinase had to be microinjected into the cells so that the 
procedure was compromised e. g. by handling a large protein (≈ 170 kDa), unequal 
distribution within the cells or toxicity due to the large amount. With the cloning of the gene 
encoding green fluorescent protein (GFP) from Aequorea Victoria and the engineering of 
mutants (such as CFP or YFP) with altered spectral properties (Tsien, 1998) the development 
of a genetically encoded PKA-based biosensor for cAMP has been facilitated (Zaccolo et al., 
2000; Zaccolo and Pozzan, 2002). Namely, the construct consisted of the regulatory RII 
subunit fused to CFP and the catalytical C subunit was tagged with YFP, so that a co-
transfection of cells had to be performed. Thus, the expression of the proteins had to be 
carefully matched in order to yield reliable FRET measurements. However, with the 
catalytically active site of C-YFP an overexpression could affect downstream targets. The A 
kinase activity reporter (AKAR) consisted of a fusion protein of CFP, the phosphoamido 
binding domain, the consensus substrate sequence for PKA and YFP (Zhang et al., 2001), an 
optimized derivative of which has been applied in a primary high-troughput screening (see 
below). Upon PKA activation by cAMP, the substrate sequence of AKAR is phosphorylated 
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and bound by its neighbouring domain. This conformational change brings the two 
fluorophores into close proximity to each other, enabling FRET. Measuring YFP and CFP 
emission (535/455 nm) upon CFP excitation (440 nm) the ratio of the fluorescence intensities 
can be calculated. In this case, the change in the ratios was between 25 to 50 %. Further single 
molecule biosensors for cAMP are, as already mentioned in section 1.3.1, derived from the 
exchange protein directly activated by cAMP (Epac). Either the whole Epac protein (DiPilato 
et al., 2004; Ponsioen et al., 2004) or a truncated version of Epac, consisting of the cAMP 
binding site (Nikolaev et al., 2004), are sandwiched between CFP and YFP. Though, 
emphasis was put on real-time imaging of cAMP in living cells by monitoring changes in the 
CFP/YFP ratio after stimulation of the cells, there have been some attempts to use the FRET 
based sensors in primary HTS (96-well format), i. e. for initial testing of compounds at a 
single concentration, in combination with subsequent secondary assays. For that purpose 
either AKAR3 or the indicator of cAMP using epac 3 were expressed as cAMP probes (Allen 
et al., 2006). Live cell plate reading was accomplished in the 96-well format by excitation at 
420 nm and emission recording at 475 and 535 nm. Maximal changes in the ratio were ≈ 25 % 
and ≈ 43 %, respectively, after applying 50 µM of forskolin (FSK) and 100 µM of 
isobutylmethylxanthin (IBMX, a phosphodiesterase (PDE) inhibitor, to prevent cellular 
cAMP degradation). Motivated by these reports from literature, the development of a 
functional FRET based cAMP assay for the human NPY Y1 receptor, using Epac2-camps (see 
below) in SK-N-MC cells, was aimed at. 
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3.2 Materials and Methods 
3.2.1 Materials 
The plasmid encoding Epac2-camps, pcDNA3-EYFP-Epac2B(murine)-ECFP (abbreviated as 
pcDNA3-Epac2-camps) was a kind gift from Dr. V. O. Nikolaev (University of Würzburg, 
Germany) and was subcloned into the pcDNA3.1(+)Zeo vector by J. Mosandl (University of 
Regensburg, Germany) using the restriction sites HindIII and NotI. The plasmids for the 
enhanced cyan fluorescent protein, pECFP-N1 and the enhanced yellow fluorescent protein 
pEYFP-N1 were from Clontech (Saint-Germain-en-Laye, France). Forskolin (ICN 
Biomedicals, Eschwege, Germany) was prepared as a stock solution (10 mM) in DMSO and 
kept at -20 °C. Dilutions were prepared in 50 % DMSO. The phosphodiesterase (PDE) 
inhibitor IBMX (Sigma, Deisenhofen, Germany) was used as a 10 mM solution in 50 % 
ethanol. 
 
3.2.2 Cell culture 
SK-N-MC cells were maintained in EMEM containing NEAA, 2.2 g/l NaHCO3, 110 mg/l 
sodium pyruvate and 10 % FCS (Biochrom, Berlin, Germany). Subculturing was performed 
every week by 1:10 dilution. Cells transfected with pcDNA3.1(+)Zeo-epac2-camps were kept 
under selection with 300 µg/ml of zeocin (Cayla SAS, Toulouse, France) (see next section). 
 
3.2.3 Chemosensitivity assay 
The chemosensitivity assay was performed according to Bernhardt et al. (Bernhardt et al., 
1992). Briefly, SK-N-MC cells were seeded 100 µl/well in transparent 96-well plates 
(Greiner, Frickenhausen, Germany) to a density of approximately 15 cells/microscopic field 
(magnification 320x). After 2-3 days the culture medium was removed by suction and 200 µl 
new medium containing increasing concentrations of zeocin were added. Two rows (16 wells) 
per plate contained vehicle instead of antibiotic as control. Zeocin was added as 1000-fold 
concentrated feed solutions. Two rows per plate were used for the incubation with each 
concentration. Approximately every 24 hours cells from a plate were fixed with 
glutardialdehyde (Merck, Darmstadt, Germany) and stored in a refrigerator. At the end of the 
experiment the cells were stained with 0.02 % crystal violet (Serva, Heidelberg, Germany) 
simultaneously. Plates were rinsed with water to remove excess dye, and cell-bound crystal 
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violet was extracted with 70 % ethanol for three hours under shaking. Subsequently, 
absorbance was measured at 578 nm using a Biotek 309 Autoreader (Tecnomara, Fernwald, 
Germany). Growth curves were constructed using the Prism 5.01 software (GraphPad, San 
Diego, CA). Absorbance values were transformed into corrected T/C values, expressing the 
net growth of the treated cells, relative to the growth of the vehicle control. Cytotoxic effects 
were comparable at all concentrations applied, thus 300 µg/ml zeocin were used for the 
selection of transfectants. 
 
 
 
3.2.4 Transfection of SK-N-MC cells 
For stable transfection, cells were seeded in a 24-well plate (Greiner, Frickenhausen, 
Germany) and 1 µg of pcDNA3.1(+)Zeo-Epac2-camps was applied with FuGENE®6 (Roche, 
Mannheim, Germany) at a ratio of 4:9 according to the manufacturer’s instructions. After two 
days, culture medium was replaced by zeocin (300 µg/ml) containing medium. 
For confocal microscopy cells were seeded either in 8-well Lab-Tek (Nunc, Wiesbaden, 
Germany) or in µ-slide 8-well (Ibidi, Martinsried, Germany) chamber slides, and one day 
prior to the experiments transiently transfected with 0.6 µg of DNA and 1.5 µl of 
lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) per well following the manufacturer’s 
instruction. 
 
Fig. 3.1: Incubation of SK-N-MC cells with various 
concentrations of zeocin; Millipore water was used 
as negative control. ◊ vehicle; zeocin concentration: 
● 300 µg/ml, ■ 400 µg/ml and ▲ 500 µg/ml. 
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3.2.5 Spectrofluorimetry 
For spectrofluorimetry SK-N-MC cells and SK-N-MC cells, stably expressing Epac2-camps, 
were let grow to confluency in a 25-cm2 culture flask. On the day of experiment, cells were 
detached with trypsin/EDTA, washed with loading buffer (Gessele, 1998) (120 mM NaCl, 
5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2 (all from Merck), 25 mM HEPES (Sigma), 10 mM 
glucose (Merck) at pH 7.4) and adjusted to 106 cells/ml. 
Measurements were performed in a Varian Cary Eclipse fluorescence spectrometer at a 
constant temperature of 25 °C (slit width: 5 nm, scan rate: slow, PMT voltage: high). The 
excitation wavelength was 436 nm, and fluorescence emission was scanned from 450 nm to 
560 or 600 nm. Quartz UV cuvettes (Hellma, Müllheim, Germany) contained 3 ml of cell 
suspension under continuous stirring. Cells were treated with IBMX and FSK and incubated 
under stirring. For applied concentrations see section 3.3.1. 
Recorded spectra were smoothed with SigmaPlotTM using the negative exponential function 
(sampling proportion 0.05, polynomial degree 1). Fluorescence intensities at the emission 
maxima (at 485 and 535 nm) were determined from the smoothed curves and CFP/YFP ratios 
were calculated. 
3.2.6 Cell sorting 
Due to decreasing expression of Epac2-camps  after several passages (10), SK-N-MC-Epac2-
camps cells were subjected to cell sorting with a fluorescence activated cell sorter 
FACSCaliburTM (Becton Dickinson, Heidelberg Germany) to enrich transfectants in the 
culture. Therefore, cells were centrifuged at 300 g for 5 min and re-suspended at a density of  
2 · 106 cells/ml in sterile phosphate buffered saline (see 5.2.6). The fluidic system of the flow 
cytometer was disinfected by flushing with 70 % ethanol for 30 min and washed subsequently 
with sterile PBS for additional 30 min. The collection tubes were prepared by incubation with 
sterile PBS containing 4 % BSA overnight. The solution was discarded and the collection 
tubes were filled with 5 ml of EMEM supplemented with 20 % FCS before installation into 
the sorting unit of the flow cytometer. The argon laser was used to excite the YFP domain of 
the Epac2-camps protein. Instrument settings were FSC: E-1, SSC: 350V and FL-1 > 360 V 
using the single cell sorting mode. 30 – 40 ml of diluted sorted cells were centrifuged for 
10 min at 300 g and re-suspended in 500 μl of EMEM containing 20 % FCS on a 24-well 
plate. The sorted cells were expanded and maintained in EMEM supplemented with 5 % FCS 
and 300 μg/ml zeocin. However, Epac2-camps expression declined again after 7 passages 
(Fig. 3.2).  
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3.2.7 Confocal microscopy 
For confocal microscopy, stable or transiently transfected SK-N-MC cells were seeded in 8-
well chamber slides (3.2.4). At the day of image acquisition the culture medium was replaced 
with Leibovitz L15 medium (Sigma), supplemented with 5 % FCS. DRAQ5TM (Biostatus 
Limited, Leicestershire, UK) was used as a nuclear stain at a final concentration of 1 µM 
(Fig. 3.2). Images were acquired with a Carl Zeiss Axiovert 200M LSM510 confocal laser 
scanning microscope (CLSM) equipped with the Zeiss Meta system. Instrument settings (laser 
excitation wavelengths, beam paths, filter combinations) are described in the legends of the 
respective figures. Spectra were recorded with the Meta detector of the microscope, i. e. the 
sample was excited with the 458 nm beam of the Argon laser, light emitted from the 
fluorophores is split into its component wavelengths. Every 10.7 nm is sent to a separate PMT 
of the Meta detector. Spectra were extracted from intracellular regions of interest (ROIs). For 
the calculation of CFP/YFP ratios, the intensities at 483 and 526 nm were used. Cells were 
treated with 10-fold concentrated IBMX and FSK solutions as indicated in Table 3.3. 
 
3.3 Results and discussion 
3.3.1 Spectrofluorimetry 
Fluorescence spectra of SK-N-MC and untreated SK-N-MC-Epac2-camps cells are shown in 
Fig. 3.3 A. After background correction, the spectrum of SK-N-MC-Epac2-camps cells 
showed the expected two emission maxima at 485 (CFP) and 530 nm (YFP), respectively. 
Incubation of the cells with 100 µM FSK (20 min) (Fig. 3.3 B curve 2) and 50 µM IBMX 
(15 min) and 100 µM FSK (20 min) (Fig. 3.3 B curve 3) raised the CFP signal, and 
concomitantly the CFP/YFP ratio by 7.1, respectively 14.2 % (Table 3.1). This is in 
Fig. 3.2: SK-N-MC-Epac2-camps 
(7. P. after sorting), nuclei stained 
with DRAQ5TM; C-Apochromat 
40x/1.2W, Ar 458, HFT 514/633, 
BP 530-600, HeNe 633, HFT 
514/633, LP 650 
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accordance with literature as a maximum ratio change of Epac2-camps expressing HEK-β1AR 
cells upon isoprenaline stimulation was reported to amount to approx. 15 % (Nikolaev et al., 
2004). 
 
 
Table 3.1: CFP/YFP ratios of SK-N-MC-Epac2-camps cells calculated from the maxima at 
485 and 530 nm, respectively 
 untreated FSK IBMX, FSK 
Ratio (CFP/YFP) 0.759 0.813 0.866 
dRatio (relative to untreated cells) - 0.054 0.108 
 
 
 
To confirm these results, the experiment was repeated. However, as already mentioned in 
section 3.2.6, due to declining Epac2-camps expression, the difference in background 
corrected spectra became very small (Fig. 3.4), and stimulation of the cells with FSK and 
treatment with IBMX failed to give reproducible results (Table 3.2). 
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Fig. 3.3: Fluorescence spectra of SK-N-MC wild-type and SK-N-MC-Epac2-camps cells; A: Background 
corrected spectrum of SK-N-MC-Epac2-camps cells (c) was calculated by substracting the autofluorescence 
of wild type cells (b) from the spectrum of SK-N-MC-Epac2-camps cells (a). B: Background corrected, 
smoothed fluorescence spectra of untreated SK-N-MC-Epac2-camps cells (1), in the presence of 100 µM 
forskolin (2) and in the presence of 1 mM IBMX and 100 µM forskolin (3); Fluorescence values at the 
emission peaks (485 nm and 530 nm) were used for analysis. 
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Table 3.2: CFP/YFP ratios of SK-N-MC-Epac2-camps cells calculated from the maxima at 
485 and 530 nm, respectively 
 untreated FSK IBMX, FSK 
Ratio (CFP/YFP) 1.337 1.311 1.368 
dRatio (relative to untreated cells) - - 0.026 0.031 
 
 
3.3.2 Confocal microscopy 
Initially, evaluation of Epac2-camps was planned to be done by confocal microscopy. 
However, due to technical problems with the microscope, these experiments were performed 
after spectrofluorimetry. The fluorescent proteins CFP and YFP alone (Fig. 3.5) and in 
combination (Fig. 3.6) were expressed transiently in SK-N-MC cells, and fluorescence 
spectra were recorded with the CLSM upon excitation at 458 nm (argon laser). The shapes of 
the spectra are comparable with those found in literature (see also section 1.3.1). Obviously, 
in particular the spectrum of co-expressed CFP and YFP showed no FRET as the emission 
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Fig. 3.4: Fluorescence spectra of SK-N-MC wild-type and SK-N-MC-Epac2-camps cells; A: Background 
corrected spectrum of SK-N-MC-Epac2-camps cells (c) was calculated by substracting the autofluorescence 
of wild-type cells (b) from the spectrum of SK-N-MC-Epac2-camps cells (a). B: Background corrected, 
smoothed fluorescence spectra of untreated SK-N-MC-Epac2-camps cells (1), in the presence of 100 µM 
forskolin (2) and in the presence of 50 µM IBMX and 100 µM forskolin (3). Fluorescence values at the 
emission peaks (485 nm and 530 nm) were used for analysis. 
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peaks were approximately the same, which was not the case in the spectrum of SK-N-MC-
Epac2-camps cells (Fig. 3.7 A). There, the YFP peak was considerably higher. To determine 
autofluorescence, spectra of SK-N-MC wild-type cells were recorded as well (Fig. 3.7 B). 
However, only minimal fluorescence was detected. Fig. 3.7 C shows the phase contrast image 
of SK-N-MC wild-type cells in comparison to the confocal image (Fig. 3.7 B). 
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Fig. 3.6: Fluorescence spectra 
of SK-N-MC cells expressing 
CFP and YFP; Spectra were 
extracted from regions of 
interest (ROI) shown in the 
corresponding images. 
C-Apochromat 40x/1.2W, 
Ar 458, ChS: 467-606 
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Fig. 3.5: Fluorescence spectra 
of SK-N-MC cells expressing 
CFP (A), YFP (B); Spectra 
were extracted from regions of 
interest (ROI) shown in the 
corresponding images. 
C-Apochromat 40x/1.2W, 
A: Ar 458, ChS: 467-596 
B: Ar 458, ChS: 467-596 
B 
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SK-N-MC-Epac2-camps cells were treated with different concentrations of IBMX and FSK 
(as indicated in Table 3.3). 5 µM FSK are used in the enzymatic cAMP assay established in 
our work group (Gessele, 1998). At this concentration and 100 µM IBMX the cAMP 
production in SK-N-MC cells amounts to ca. 38 µM. Epac2-camps is already saturated at a 
concentration of 2 µM of cAMP to 90 %. Thus, with 5 µM FSK there should be an 
unequivocal change in the ratio of CFP/YFP intensity. In Table 3.3 the results from one 
experiment are given. Data were averaged from four cells, each. Fluorescence spectra of the 
same cells were recorded during the experiment. The change in the ratios was up to 32 % for 
FSK treatment for 10 min. Intriguingly, this change decreased to half of the value after 
another 5 min, and the cells treated with the PDE inhibitor and FSK showed poor FRET 
response. The experiment was repeated twice. However, no sensible results were obtained. 
Thus, the initial idea to develop a FRET based assay for the 96-well plate format was not 
pursued any longer. 
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Fig. 3.7: Fluorescence spectra 
of SK-N-MC-Epac2-camps 
cells (A), SK-N-MC wild-type 
cells (B), and the respective 
phase contrast image (C); 
Spectra were extracted from 
different regions of interest 
(ROI) shown in the correspon-
ding images.  
C-Apochromat 40x/1.2W, 
A: Ar 458, ChS: 467-595 
B: Ar 458, ChS: 467-606 
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Table 3.3: Ratios of CFP- and YFP-fluorescence calculated from spectra of differently treated 
SK-N-MC-Epac2-camps cells 
Treatment Ratio (483/526) dRatio (483/526) 
- 0.553 ± 0.003 - 
FSK 10 µM, 10 min 0.815 ± 0.022 0.262 ± 0.025 
FSK 10 µM, 15 min 0.668 ± 0.018 0.115 ± 0.015 
- 0.721 ± 0.023 - 
IBMX 100 µM, 10 min 
FSK 5 µM, 13 min 
0.667 ± 0.023 -0.054 ± 0.029 
- 0.672 ± 0.012 - 
IBMX 100 µM, 10 min 
FSK 5 µM, 17 min 
0.717 ± 0.033 0.044 ± 0.026 
Means ± S.E.M. (n = 4 cells from one image), dRatio (483/526) is relative to untreated cells 
 
3.4 Summary and conclusions 
The promising concept of measuring cAMP with biosensors such as Epac2-camps was 
evaluated with the aim to develop a HTS for hY1R in SK-N-MC cells. For this purpose, the 
cells were transfected with pcDNA3.1(+)Zeo-Epac2-camps. Stable transfection was not 
accomplished, because protein expression declined after as few as 7 passages, even after flow 
cytometric cell sorting. Transient tranfection was satisfactory for confocal microscopy. In a 
spectrofluorimetric assay, SK-N-MC-Epac2-camps cells showed the expected spectrum with 
emission peaks at 485 and 530 nm. However, these initial promising results, i.e. changes in 
the ratio of CFP/YFP intensities upon FSK and IBMX treatment, could not be confirmed. 
This is partly due to the poor protein expression by the transfectants. In confocal microscopy, 
spectra of CFP, YFP and Epac2-camps expressed in SK-N-MC cells had the expected shapes 
and peaks. Intriguingly, the CFP/YFP FRET change upon treatment with IBMX and FSK 
showed no usable results, although spectra were recorded from identical cells, untreated and 
treated, respectively. The FRET efficiency of Epac2-camps determined by acceptor 
photobleaching was 15 %, of which the change in the CFP/YFP fluorescence ratio upon  
isoprenalin stimulation of HEK-β1AR cells was again only 15 % (Nikolaev et al., 2004). This 
amounts approximately to 2 – 3 % of the total fluorescence. Most probably, such small 
signals can hardly be exploited for HTS. 
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4 Towards fluorescence and luminescence based functional 
assays for the human NPY Y5 receptor in HEC-1B-hY5 
cells 
 
4.1 Introduction 
4.1.1 Redirecting receptor signaling via chimeric G proteins 
Historically, cAMP inhibition of the Y5R after forskolin stimulation was measured 
radioimmunologically (Gerald et al., 1995; Gerald et al., 1996; Bischoff et al., 2001). 
Meanwhile modern assays such as a homogenous cAMP kit ((HTRF), Cisbio Bioassays, 
Bagnols-sur-Cèze Cedex, France) based on time-resolved FRET (TR-FRET) are in use 
(Kakui et al., 2006; Walker et al., 2009). In the latter, after lysis of the cells, endogeneous 
cAMP competes with e.g. phycobilin conjugated cAMP (acceptor) for the binding site of a 
cryptate-labeled cAMP antibody (donor), thereby eliminating FRET. Though this approach 
exhibits high sensitivity, reproducibility and precision (De los Frailes and Diez, 2009), it has 
the disadvantage of high costs regarding small scale laboratory use. The same is true for 
GTPγ35S binding assays based on scintillation proximity with membranes of mY5R 
expressing HEK293 cells (Dautzenberg et al., 2005). 
Ca2+ mobilization is the most versatile and convenient way to measure signals within cells. 
The two main technologies to quantify intracellular Ca2+ in high throughput screening (HTS) 
mode use Ca2+-sensitive dyes (fluorescent assays) or photoproteins (luminescence assays) (De 
los Frailes and Diez, 2009). The hY5R has been shown to elicit Ca2+ signals upon stimulation, 
when expressed in LMTK cells heterologously. This system was used for determination of Y5 
ligand activities (Criscione et al., 1998; Kanatani et al., 2000). Moreover, a combination of 
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the receptor with chimeric G proteins like Gαqi5, Gαqi9 or Gαq/z5 in CHO, HEK293 or COS-7 
cells was efficient for this purpose (Dautzenberg et al., 2005; Sato et al., 2008; Ando et al., 
2009; Walker et al., 2009).  
So far, bioluminescence assays for the Y5 receptor have not been described. Advantages of an 
aequorin assay are for example: no dye leakage, no requirement for excitation light, no photo-
bleaching, no auto-fluorescence or biological degradation problems. Menon et al. also 
reported on a significant decrease in the number of false-positives with the aequorin assay 
(Menon et al., 2008). Therefore, the HEC-1B-hY5 cell line (established at our work group) 
was used first to establish fluorescence based Ca2+ assays, becoming feasible via chimeric G 
proteins. Subsequently exploitation of mitochondrially targeted aequorin (mtAEQ) as calcium 
sensor was probed. 
 
 
4.2 Materials and Methods 
4.2.1 Preparation of media and agar plates 
LB medium containing 1 % bacto tryptone (Difco, Detroit, MI), 0.5 % yeast extract (Carl 
Roth GmbH, Karlsruhe, Germany) and 1 % NaCl (Merck, Darmstadt, Germany) was prepared 
in millipore water, and the pH was adjusted to 7.0. For sterilization the medium was 
autoclaved at 121 °C for 20 min and then stored at 4 °C until use. Selective amp-LB medium 
was prepared by adding ampicillin (Sigma, Deisenhofen, Germany) from a sterile stock 
solution in millipore water (100 mg/ml) to the LB medium to yield the final concentration of 
100 µg/ml.  
For the preparation of selective agar plates, 1.5 % agar (Carl Roth GmbH) was added to 1000 
ml of LB medium. After sterilization by autoclaving, the medium was cooled to 60-65 °C, 
ampicillin was added (as described above) and plates were prepared under LAF conditions. 
Selective plates were stored at 4 °C for 8 to 12 weeks.  
SOC medium contained 2.5 mM KCl (Merck), 10 mM MgCl2 (Merck) and 10 mM MgSO4 
(Merck) in LB medium. After autoclaving a sterile glucose (Merck) solution was added to 
yield a final concentration of 20 mM. 
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4.2.2 Preparation of competent E. coli 
Competent cells were prepared using the E. coli TOP10 strain (Invitrogen, Karlsruhe, 
Germany). 5 ml of an overnight culture were grown in LB medium. Then 200 ml of sterile LB 
medium were inoculated with 2 ml of the overnight culture. Cells were grown with shaking 
(190 rpm) at 37 °C to an OD600 of 0.2. The bacterial suspension was aliquoted into 8 pre-
chilled, sterile polypropylene tubes and left on ice for 10 min. Cells were collected by 
centrifugation at 1500 g for 7 min at 4 °C, the supernatant was discarded and each cell pellet 
was re-suspended in 5 ml of ice-cold CaCl2 solution containing 60 mM CaCl2 (Merck), 
10 mM PIPES (Gerbu, Gaiberg, Germany) and 15 % glycerol (Merck) at pH 7.0. Cells were 
centrifuged for 5 min at 1000 g, re-suspended in 5 ml of ice-cold CaCl2 solution and 
incubated on ice for 30 min. After another centrifugation step at 1000 g for 5 min, the 
supernatant was poured off, and each pellet was re-suspended in 1 ml of ice-cold CaCl2 
solution. 100 µl aliquots of cell suspension were pipetted into 1.5 ml microfuge tubes and left 
on ice for another 2 h. Finally, competent cells were frozen in liquid nitrogen and stored at -
80 °C. 
 
4.2.3 Transformation of E. coli 
For chemical transformation, 200 µl of a suspension of competent cells were thawed on ice 
and the plasmid DNA or the ligation product was added prior to incubation on ice for 30 min. 
Cells were heat-shocked by transferring the tubes into a 42 °C warm water bath for 90 min. 
For recovery and the expression of the antibiotic resistance gene needed for the positive 
selection of the transformants,  1 ml of SOC medium, pre-warmed to 37 °C, was added, and 
the bacteria were incubated for 45 min at 37 °C with shaking (200 rpm). 
20 µl of the transformant suspension were plated onto selective agar and the plates were 
incubated overnight at 37 °C. Colonies were picked and used for overnight cultures in 
selective medium. 
 
4.2.4 Preparation of plasmid DNA 
4.2.4.1 Miniprep 
For the preparations of DNA small scale alkaline lysis procedures were performed according 
to the protocol described by Birnboim and Doly (1979). Buffers were prepared as follows: 
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Buffer P1: 50 mM Tris·HCl (Serva, Heidelberg, Germany), 10 mM titriplex III (Merck) and 
100 µg/ml RNase A (MBI Fermentas, St. Leon-Rot, Germany) in millipore water, pH 8.0 
Buffer P2: 0.2 M NaOH (Merck) and 1 % SDS (Sigma) in millipore water 
Buffer P3: 3 M KAc (Merck) in millipore water, pH 5.5 
5 ml of amp-LB selective medium were inoculated with bacteria from an isolated colony and 
incubated overnight at 37 °C under vigorous shaking (200 rpm). 1.5 ml of this culture was 
centrifuged for 30 s at 13,000 rpm (Eppendorf Centrifuge 5415 R, Eppendorf, Hamburg, 
Germany). The supernatant was discarded and the cell pellet was re-suspended in 100 µl of 
P1. For the degradation of bacterial RNA the suspension was incubated for 5 min at room 
temperature. Addition of 200 µl of P2 resulted in cell lysis. The solution was mixed gently by 
inverting the tubes several times, before another 5 min of incubation on ice. Addition of 150 
µl of ice-cold P3 and further incubation for 10 min led to neutralization of the lysate and 
precipitation of SDS, denaturation of proteins and chromosomal DNA. Separation of the 
precipitate from solution was achieved by centrifugation at 13,000 rpm for 15 min. Further 
purification of the plasmid in the supernatant resulted from the addition of 400 µl of phenol-
chloroform-isoamylalcohol (25:24:1) (Carl Roth GmbH), vigorous vortexing and separation 
of the phases by centrifugation at 13000 rpm for 3 min. The aqueous phase was transferred 
into a new tube and plasmid DNA was precipitated by addition of 1 ml of ice-cold ethanol 
(Mallinckrodt Baker, Griesheim, Germany) and centrifugation at 13000 rpm for 20 min. 
Finally, the pellet was washed with 1 ml of ethanol (70 %), air dried and dissolved in 10 µl of 
millipore water. The DNA solutions were stored at -20 °C. 
Usually Mini-Preps were done in parallel (3 x 1.5 ml of each preparation) and the solutions 
were pooled to obtain larger amounts of plasmid DNA for analytical purposes. 
 
4.2.4.2 Maxiprep 
For large scale plasmid preparation, the Qiagen Plasmid Maxi Purification Kit (Qiagen, 
Hilden, Germany) was used according to the manufacturer’s instructions.  
 
4.2.4.3 Determination of DNA concentration and sequencing 
Usually, a 1:70 dilution of Mini-Prep or Maxi-Prep DNA was prepared and spectra were 
recorded with a Cary 100 UV-Vis spectrophotometer (Varian, Darmstadt, Germany). DNA 
concentration was determined according to the following equation: c [µg/ml] = 50 · A260 · 
dilution factor, according to the assumption that a double stranded DNA solution of 50 µg/ml 
 Fluorescence and luminescence based functional assays for the NPY Y5 receptor 41 
has an absorbance of 1.0 at 260 nm when the path length is 1 cm. Sequencing was performed 
by Entelechon (Regensburg, Germany). 
 
4.2.4.4 Restriction enzyme digestion and dephosphorylation of plasmid ends 
For the subcloning of PCR products and restriction enzyme analysis of plasmid DNA the 
enzymes BamHI (MBI Fermentas, St. Leon-Rot, Germany) and EcoRV (MBI Fermentas) 
were used. The reaction buffer (SuRE/Cut buffer B, Roche) was chosen to assure 100 % 
activity for each enzyme. Usually samples were digested in 20 µl of reaction volumes 
containing 2 µl of reaction buffer, 1 µl of each enzyme (10 U) and 0.5 – 2.0 µg of DNA. The 
reaction was carried out for one hour at 37 °C in an Eppendorf reaction vessel and enzymes 
were heat inactivated for 15 min at 70 °C. 
In order to avoid self ligation of digested plasmid, the DNA ends were dephosphorylated with 
calf intestine phosphatase (CIP; Boehringer Mannheim, Mannheim, Germany) by incubation 
at 37 °C for 1 h. Heat inactivation of the CIP followed for 20 min at 80 °C. Required CIP 
units for reaction were calculated according to the amount of digested plasmid DNA (1 pmol 
DNA ends correspond for 0.05 U of CIP). 
 
4.2.4.5 Agarose gel electrophoresis 
Agarose gels were prepared by dissolving 0.75 or 1.0 g of agarose (pegGOLD Universal-
Agarose, Peqlab, Erlangen, Germany) under heating and stirring in 50 ml of TAE buffer (used 
as a dilution from a 50x concentrated stock solution containing 242 g Tris base (usb, 
Cleveland, OH), 57 ml of glacial acetic acid (Merck) and 100 ml of EDTA solution (0.5 M, 
pH 8.0; Merck) in 1000 ml of millipore water). To visualize DNA, 2 µl of an ethidium 
bromide (Janssen Chimica, Beerse, Belgium) solution (10 mg/ml) were added. The warm 
agarose solution was poured into the gel chamber and let gel for 30 min.  
Prior to electrophoresis, TAE buffer was filled into the gadget, 6x DNA loading dye (MBI 
Fermentas) was added to the samples from PCR or restriction enzyme digestion and the 
mixtures were pipetted into the pockets. For analytical gels usually 5 µl of PCR product or 
digested DNA mixed with 1 µl of loading dye were applied. For quantitative gels after 
restriction enzyme digestion volumes up to 30 µl were pipetted into gels with larger pockets. 
As reference, 5-10 µl of the MassRulerTM DNA ladder Mix (#SM0403; MBI Fermentas) were 
used. 
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Electrophoresis was performed 60-90 min at 90 V until the track dye moved 2/3 of the gel 
length. Then, the gel tray was removed from the electrophoresis chamber and DNA bands 
were visualized by illumination with UV light at 254 nm (Gel Doc 2000; Bio-Rad 
Laboratories, München, Germany). Quantity One (Bio-Rad) software was used for data 
analysis. 
DNA concentration of the sample was roughly estimated by comparing the intensities of the 
bands with the intensity of the band of the DNA ladder corresponding to the sample in size 
according to the manufacturer´s information. 
 
4.2.4.6 Purification of PCR product and recovery of DNA fragments from agarose gels 
DNA from PCRs was desalted and the polymerase was removed with the QIAquick PCR 
Purification Kit (Qiagen, Hilden, Germany). After restriction enzyme digestion DNA 
fragments were first separated by agarose gel electrophoresis. Bands with the correct sizes 
were excised from the gel under UV light (λex 254 nm) and extracted with the QIAEX II Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions. Depending on the 
volume of the PCR reaction mixtures, DNA was eluted with 10-50 µl of millipore water. 
Subsequent to purification, DNA concentration was assessed as described (cf. section 4.2.4.5). 
 
4.2.5 Preparation of chimeric Gαqi9 by PCR 
The nucleotide sequence of Gαqi5 encodes a chimeric Gα-protein representing Gαq with the 
last 5 C-terminal amino acids changed into the sequence of Gαi2, thereby enabling Gi-coupled 
receptors to signal via calcium mobilization. Since Dautzenberg et al. reported that the human 
and the murine Y5 receptor would exclusively couple to Gαqi9 (Dautzenberg et al., 2005), 
Gαqi5 was further modified by PCR. With the antisense primer the triplet CTG, encoding the 
9th amino acid (counted from the C-terminus), was exchanged (AAC) so that lysine was 
mutated into asparagine, which is the corresponding amino acid in Gαi in that position. In 
PCR reactions 100 ng of the plasmid pcDNA3.1/Hygro-Gαqi5, prepared by R. Ziemek (Dept. 
of Pharmaceutical Chemistry II, University of Regensburg, Germany), was used as template. 
The primers were obtained from MWG (Ebersberg, Germany). 
 
Gqi9-(T7)-sense 5’ - TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TGG - 3’ 
Gqi9-EcoRV-anti:  5’ - CGC GAT ATC ATG CAT TCA GAA GAG GCC ACA GTC 
CTT AAG GTT GTT CTG CAG GAT GGT - 3’ 
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If not stated otherwise, all other reagents were from MBI Fermentas Life Sciences,. PCR 
reaction mixtures contained 2.5 U of recombinant Pfu DNA Polymerase, 10 µl 10x Pfu buffer 
without MgSO4, 3.5 mM MgSO4, dNTP Mix (0.2 mM each) and primers (0.5 µM each) in a 
final volume of 100 µl. 10 % DMSO was added to prevent annealing of template cDNA. PCR 
reactions were performed in a Mastercycle gradient Thermocycler (Eppendorf, Hamburg, 
Germany). 
Cycling parameters were: 
(1) initial denaturation 95 °C, 3 min 
(2) denaturation  95 °C, 1 min 
(3) annealing  60 °C, 2 min 
(4) extension  72 °C, 2 min 
(5) final extension  72 °C, 5 min 
(6) hold       4 °C 
Steps (2) to (4) were repeated 24 times. 
The expected size of PCR product was 1167 bp, which 
was found in agarose gel electrophoresis subsequently, as 
shown in Fig. 4.1.  
 
4.2.6 Subcloning of pcDNA3.1/Hygro-Gαqi9 
The PCR product and the template pcDNA3.1/Hygro-Gαqi5 were digested and the plasmid 
ends were additionally dephosphorylated as described in 4.2.4.4. After electrophoresis 
(Fig. 4.2 A), the amount of DNA was assessed, bands were excised from the agarose gel and 
DNA fragments were extracted. 240 ng of plasmid was incubated with each a 5- and 2-fold 
molar excess of insert for ligation. Reactions in mixtures containing 5 Weiss units of T4 DNA 
ligase (MBI Fermentas), 2 µl of 10x ligation buffer (MBI Fermentas) and water in a final 
volume of 20 µl were carried out overnight at room temperature. After transformation of the 
ligation products in competent E. coli minipreps of plasmids were prepared. Restriction 
enzyme analysis was performed with BamHI and EcoRV (Fig. 4.2 B). Sequencing proved the 
insertion of the PCR product Gαqi9 with three mutations (A1051C, A1052T and C1053G 
counted from the ATG of the gene) compared to pcDNA3.1/Hygro-Gαqi5 prepared by R. 
Ziemek (Ziemek, 2006). 
 
500 
1000 
1500 
1167 
Fig. 4.1: Agarose gel (2%) 
electrophoresis of PCR product Gαqi9; 
Numbers indicate the sizes of bands in 
the DNA ladder in base pairs (bp). 
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4.2.7 Cell culture and chemosensitivity assay 
HEC-1B-hY5 cells (Moser et al., 2000) were maintained in EMEM containing NEAA, 2.2 g/l 
NaHCO3, 110 mg/l sodium pyruvate, 10 % FCS (Biochrom, Berlin, Germany) and 400 μg/ml 
G418. Subculturing was performed weekly by 1:10 dilution. 
For transfection pcDNA3.1/Hygro-Gαqi5/9 and pcDNA3.1/Zeocin-mtAEQ were used, which 
encode the hygromycin and the zeocin resistence gene, respectively. The cells were tested for 
their sensitivity to the antibiotics, hygromycin B (MoBiTec GmbH, Göttingen, Germany) and 
zeocin (Cayla SAS, Toulouse, France), in a chemosensitivity assay as described in section 
3.2.3. At all tested concentrations, hygromycin showed similar cytotoxicity (Fig. 4.3 A), so 
that a concentration of the antibiotic of 250 µg/ml was chosen for the selection of transfected 
cells. Zeocin showed cytotoxicity at a concentration of 100 µg/ml, which was used for the 
selection of transfectants (Fig. 4.3 B). 
 
 
Fig. 4.2: Restriction enzyme digestion of PCR product Gαqi9 and pcDNA3.1/Hygro-Gαqi5 (A) 
and restriction enzyme analysis of minipreps (pcDNA3.1/Hygro-Gαqi9) from ligation reactions 
with different molar ratios of insert to plasmid as indicated below lanes (B) 
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4.2.8 Transfection of HEC-1B-hY5 cells with pcDNA3.1/Hygro-Gαqi5/9 
HEC-1B-hY5 cells were seeded in 25-cm2 cell culture flasks or in 24 well plates (Thermo 
Fisher Scientific GmbH, Bonn, Germany) and transfected with FuGENE 6 or FuGENE HD 
(Roche, Mannheim, Germany) according to the manufacturer’s protocol and Table 4.1: 
 
Table 4.1: Overview of transfection procedures for HEC-1B-hY5 cells 
Cells Culture 
dish 
pcDNA 
3.1/Hygro-
Gαqix 
Transfection 
reagent 
DNA:Fu
GENE 
Ratio 
Tested 
clone 
See 
Fig. 
HEC-1B-hY5, 
64. P 
25 cm2 flask Gαqi5 
4 µg 
FuGENE 6 
9 µl 
1 : 2.25 qi5 4.4 – 
4.6 
HEC-1B-hY5, 
119. P 
24 well Gαqi5 
0.4 µg 
FuGENE HD 
4 µl 
1 : 10 H1 4.7 
HEC-1B-hY5, 
119. P 
24 well Gαqi9 
0.4 µg 
FuGENE HD 
4 µl 
1 : 10 J1 4.7 
HEC-1B-hY5, 
29. P 
24 well Gαqi5 
1.5 µg 
FuGENE HD 
4.5 µl 
1 :3 62a 4.8 
HEC-1B-hY5, 
29. P 
24 well Gαqi9 
0.5 µg 
FuGENE HD 
4 µl 
1 : 8 82 4.8 – 
4.9 
Fig. 4.3: Incubation of HEC-1B-hY5 cells with various concentrations of hygromycin (A) and zeocin (B); 
Millipore water was used as negative control. A: ◊ vehicle; hygromycin concentration: ● 100 µg/ml, 
○ 250 µg/ml, ■ 350 µg/ml and □ 500 µg/ml. B: ◊ vehicle; zeocin concentration: ● 50 µg/ml, ○ 100 µg/ml, 
■ 200 µg/ml and □ 500 µg/ml 
A B 
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Usually, two days after transfection the culture medium was replaced with selective medium, 
which was exchanged every 4-5 days until the cells from control dishes had died and the 
colonies formed by the transfected cells were big enough for passaging. Subsequently the 
transfectants were tested in either flow cytometric or spectrofluorimetric calcium assays as 
described in the following sections. 
 
4.2.9 Transfection of HEC-1B-hY5-Gαqi5/9 with pcDNA3.1/Zeo-mtAEQ 
The mtAEQ cDNA was subcloned into the pcDNA3.1/Zeo vector by R. Ziemek. HEC-1B-
hY5-Gαqi5 (clone 62a) and HEC-1B-Gαqi9 (clone 82) cells were seeded in 24 well plates. 
Transfection was accomplished with 0.8 µg of plasmid DNA and 1.2 µl (clone 62a), 
respectively 1.8 µl (clone 82) of FuGENE 6 transfection reagent (Roche) according to the 
manufacturer’s protocol. Transfectants were selected in the presence of 100 µg/ml zeocin and 
tested as described (cf. sections 4.2.8 and 4.2.12). 
4.2.10 Flow cytometric calcium assay 
The assay was essentially performed as described by Ziemek (2006). Cells were grown for 2-
3 days to 70-90 % confluency, trypsined and EMEM 10 % FCS was added to inactivate 
trypsine before detaching the cells from the bottom of the flask. Afterwards cells were 
counted and centrifuged for 5 min at 300 g. Cell density was adjusted to 2.66 · 106 cells/ml in 
loading buffer (Gessele, 1998) containing 120 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM 
CaCl2 (all from Merck), 25 mM HEPES (Sigma) and 10 mM glucose (Merck) at pH 7.4. The 
dye suspension was prepared by mixing 3 µl of fluo-4-AM (Molecular Probes; 1 mM stock 
solution in anhydrous DMSO) with 5 µl of pluronicTM F-127 (Molecular Probes; 20 % stock 
solution in DMSO) before the addition of 1 ml of loading buffer containing 2 % BSA (VWR 
International, Poole, England). 330 µl of the dye suspension were added to 1 ml of cell 
suspension resulting in a cell number of 2 · 106 cells/ml and a dye concentration of 0.7 µM. 
Cells were incubated in the dark for 30 min at room temperature. After centrifugation at 300 g 
for 5 min and suspending of the pellet in fresh loading buffer to a density of 0.5 – 1 · 106 
cells/ml, the cells were incubated again to enable the cleavage of the acetoxymethylester by 
intracellular esterases. Thereby, carboxylic groups are exposed and due to its negative charges 
the calcium chelator is trapped within the cells. 
Measurements were performed in a purpose-built glass tube closed by a silicon septum as 
described (Schneider, 2005). This instrumentation allows injections into the samples during 
continuous flow cytometric measurements. A tube containing 1 ml of the cell suspension was 
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connected with a FacsCaliburTM flow cytometer (Becton Dickinson, Heidelberg, Germany) 
under permanent stirring, and recording was started. Instrument settings were: FSC: E-1, SSC: 
280, FL-1: 350, flow: high. 
During the first 30 s basal fluorescence was measured, then 10 µl of pNPY solution were 
injected with a Hamilton syringe, and data acquisition continued for another 90 s. Raw data 
were averaged with the WinMDI 2.8 software and then exported to SigmaPlotTM 11.0.1. Data 
were further smoothed (running average) with SigmaPlotTM. The level of increase in 
fluorescence was calculated from the difference between the baseline (mean fluorescence of 
the first 25 s) and the highest value of the averaged curve. The amplitudes of the averaged 
signals were used to construct concentration response curves. The EC50 value was calculated 
using the equation of the four parameter logistics function. 
10 µl of a tenfold solution of CGP 71638A (see structure in section 1.2.3), prepared in an 
equal mixture of DMSO and 10 mM HCl, was incubated with 990 µl of cell suspension for 1 
min prior to measurement. Calcium response was triggered with various concentrations of 
pNPY as indicated in the figures in section 4.3.1. 
 
4.2.11 Spectrofluorimetric calcium assay 
The spectrofluorimetric calcium assay was performed with the ratiometric Ca2+ indicator fura-
2 as described by Gessele (1998) for HEL cells. HEC-1B-hY5-Gαqix cells were grown for 2-3 
days to 70-80 % confluence, trypsinized and detached with EMEM 10 % FCS. Cells were 
counted, centrifuged at 300 g for 5 min and resuspended at 1.3 · 106 cells/ml in loading buffer. 
The dye suspension was prepared by mixing 4 µl of fura-2-AM (Molecular Probes; 1 mM 
stock solution in anhydrous DMSO) with 5 µl pluronicTM F-127 (Molecular Probes; 20 % 
stock solution in DMSO) before the addition of 1 ml of loading buffer containing 2 % BSA. 
250 µl of the dye suspension were added to 750 µl of cell suspension resulting in a cell 
number of 1 · 106 cells/ml and a dye concentration of 1 µM. Cells were incubated for 30 min 
at room temperature in the dark, centrifuged at 300 g for 5 min, re-suspended in the same 
volume of loading buffer and incubated another 30 min at room temperature in the dark. 
Subsequently, the cells were washed twice with loading buffer, and the suspension was 
adjusted to a density of 1 · 106 cells/ml. 
Measurements were performed in a Perkin Elmer LS 50 B spectrofluorimeter (Perkin Elmer, 
Überlingen, Germany) at 25 °C under continuous stirring (low). Instrument settings were: 
λex: 340 nm and 380 nm (alternating) with slit: 10 nm and λem: 510 nm with slit: 10 nm.  
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For measurements, 1 ml of the cell suspension was transferred into disposable cuvettes 
containing 1 ml of loading buffer under continuous stirring. The baseline was recorded for 30 
s before the agonist was added. Antagonists were incubated with the cells 30 s prior to 
measurement. 
For the calculation of the calcium concentration the Grynkiewicz equation (Grynkiewicz et 
al., 1985) was used: 
SFB
RR
RRKCa D ⋅−
−⋅=+
)(
)(][
max
min2  
Equation 4.1 
 
Explanations: 
KD dissociation constant of fura-2-Ca2+ (= 225 nM) 
R ratio of fluorescence intensity at 510 nm after excitation at 340 nm and 380 nm 
Rmax fluorescence ratio in presence of saturating Ca2+ concentration, determined by the 
addition of 10 µl of digitonin (2 % in water, Sigma), which caused lysis of the cells 
and saturation of the dye with the calcium ions of the loading buffer. 
Rmin fluorescence ratio of calcium free dye, which was achieved by the addition of 50 µl of 
EGTA solution (600 mM in 1 M Tris·HCl buffer, pH 8.7) to the lysed cells. 
SFB correction factor; the ratio of fluorescence intensity at 510 nm after excitation at 380 
nm of the Ca2+ free and the calcium saturated dye. 
 
4.2.12 Aequorin assay  
Cells were seeded into 25-cm2 culture flasks and grown to 80-90 % confluency, trypsinized 
and adjusted to 10·106/ml in DMEM, supplemented with 1 % FCS and 2 µM coelenterazine h 
(Biotrend GmbH, Köln, Germany). The suspension was kept under gentle stirring in the dark 
for 2 h. Loading buffer (cf. section 4.2.10) was added to dilute the suspension (1:20), and the 
cells were incubated for another 3 h. This time period assures the complete reconstitution of 
the apoprotein aequorin with its cofactor colelenterazine h. 180 µl of cell suspension were 
pipetted per well into a white 96-well luminescence plate (Nunc, Wiesbaden, Germany). The 
plate was inserted into the GENios ProTM (Tecan, Salzburg, Austria) plate reader and 20 µl 
of 1 % triton-X-100 in loading buffer were injected per well. Upon addition of the non-ionic 
surfactant the cells are lysed and entering Ca2+ from the loading buffer triggers the oxidation 
of coelenterazine and thereby the emittance of light. Luminescence was recorded for 20 s in 
200 ms integration steps (instrument setting: no attenuation). 
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4.3 Results and discussion 
4.3.1 Flow cytometric calcium assay 
Upon stimulation of hY5R in HEC-1B-hY5 cells lacking Gαqi5, only small Ca2+ transients 
were recorded (at high concentrations of pNPY (100 nM); Fig. 4.4). This is in agreement with 
published results (Bischoff et al., 2001). On the contrary, with Gαqi5 expressing HEC-1B-hY5 
cells a robust Ca2+ signal was obtained 
in the flow cytometric fluo-4 assay (Fig. 
4.4 and 4.5). From the amplitudes of the 
fluorescence signals a concentration 
response curve of pNPY was 
constructed. The calculated EC50 is in 
agreement with data from literature 
(Gerald et al., 1996; Bischoff et al., 
2001; Dautzenberg et al., 2005). 
Moreover, Ca2+ mobilization could be 
inhibited by the Y5 receptor antagonist 
CGP 71683A (Fig. 4.6), indicating a 
Y5R mediated effect. 
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Fig. 4.5: Base line corrected fluorescence signals of Fluo-4 loaded HEC-1B-hY5-Gαqi5 cells with various 
concentrations of pNPY and concentration response curve of pNPY; Fluorescence was measured in the FL-1 
channel of the flow cytometer. (A) The concentration response curve of pNPY (B) was constructed from the 
experiment shown in (A). Data were calculated from baseline corrected mean fluorescence signals related to the 
maximum signal with 1 µM pNPY. The determined EC50 value is 8.3 nM. 
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Fig. 4.4: Basal and stimulated (100 nM pNPY) 
fluorescence signal of Fluo-4 loaded HEC-1B-hY5 
and HEC-1B-hY5-Gqi5 cells 
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However, after several passages of the co-transfectants, no calcium signal was detectable 
(data not shown), probably because the expression of the chimeric G protein was not stable. 
Therefore, cells were newly transfected with Gαqi5 and Gαqi9, respectively. Mobilization of 
intracellular Ca2+ was mediated by both chimeric G proteins to approximately the same extent 
(Fig. 4.7). However, compared to the former experiment (Fig. 4.5) the amplitude of the 
calcium signal triggered by 100 nM pNPY was only about one-fifth (with Gαqi5; Fig. 4.7 A) 
and one-fifteenth (with Gαqi9, Fig. 4.7 B), respectively. This is presumably due to the high 
passage (119. P) of the HEC-1B-hY5 cells used for the generation of the latter transfectants 
(Table 4.1), in which the expression level of the NPY Y5 receptor was insufficient. Therefore, 
transfections were repeated with HEC-1B-hY5 cells from a lower passage (29. P; Table 4.1). 
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Fig. 4.7: Mean fluorescence signals of Fluo-4 loaded HEC-1B-hY5-Gqi5 (A) and HEC-1B-hY5-Gqi9 (B) cells from 
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Fig. 4.6: Baseline corrected mean 
fluorescence signals of Fluo-4 loaded 
HEC-1B-hY5-Gqi5 cells from a flow 
cytometric calcium assay 
A: Baseline 
B: 1 nM pNPY 
C: 10 nM pNPY 
D: 1 nM pNPY, 100 nM CGP 71683A,  
E: 10 nM pNPY, 1 µM CGP 71683A.  
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4.3.2 Spectrofluorimetric calcium assay 
When stimulated with 1 µM pNPY, both, Fura-2 loaded HEC-1B-hY5-Gαqi5 and HEC-1B-
hY5-Gαqi9 showed an increase in intracellular calcium by about 100 nM and 150 nM, 
respectively in spectrofluorimetric Ca2+ assays (Fig. 4.8). However, these Ca2+ transients are 
quite low, when compared to signals (600 nM) e.g. elicited in CHO-hY2-Gαqi5 by pNPY 
concentrations as low as 50 nM (Ziemek, 2006). In the absence of chimeric G proteins, hY5R 
did not mediate Ca2+ mobilization, presumably, due to the fact that by spectrofluorimetry the 
mean signal of the total cell population 
is recorded, while the flow cytometric 
Fluo-4 assays allows for gating of the 
cells of interest. 
 
HEC-1B-hY5-Gαqi9 cells were serially 
passaged over three weeks and tested 
for their calcium signal. As shown in 
Fig. 4.9, 1 µM pNPY elicited a robust 
response, however there was poor 
responsiveness to low concentrations of 
pNPY (A). Calcium signals were 
inhibited by the Y5 antagonist (B). 
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Fig. 4.9: Calcium mobilization in Fura-2 loaded HEC-1B-hY5-Gqi9 cells with varying pNPY concentrations in a 
spectrofluorimetric calcium assay (A) and in the presence of the Y5 receptor antagonist CGP 71683A (B); a: 
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HEC-1B-hY5, HEC-1B-hY5-Gqi5 and HEC-1B-hY5-
Gqi9 cells by 1 µM pNPY measured in a 
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4.3.3 Aequorin assay 
HEC-1B-hY5-Gαqi5-mtAEQ and HEC-1B-hY5-Gαqi9-mtAEQ were tested for their expression 
of aequorin. Cells were loaded with the cofactor coelenterazine h to reconstitute the 
holoprotein. Upon injection of triton-X-100 at a final concentration of 0.1 %, the nonionic 
surfactant causes cell lysis, thereby allowing Ca2+ to enter with the loading buffer. 
Subsequently, if aequorin is expressed, the oxidation of the cofactor to coelenteramide takes 
place and luminescence occurs (λ = 470 nm). Fig. 4.10 shows that only the cells expressing 
Gαqi9 were able to emit light, i.e. in this case the transfection was successful. In the aequorin 
assay triton-X-100 is used to lyse the cells after the Ca2+ signal, in order to determine the total 
luminescence within a well. Thus, by calculating fractional luminescence i.e. signal elicited 
by the ligand relative to total luminescence) the measurement becomes independent of 
variability in cell number. Regarding the fact that the testing was conducted at exactly the 
same conditions as the established assay, the light emitted from the HEC-1B-hY5-Gαqi9-
mtAEQ cells corresponds to only about 4 % of the intensity of the “triton-X-signals” from 
CHO-hY2/4-Gαqi5-mt AEQ. Therefore, the development of such an assay was no longer 
pursued. 
 
 
 
 
 
 
 
Fig. 4.10: Luminescence signal of 
HEC-1B-hY5-Gαqi5-mtAEQ (A) and 
HEC-1B-hY5-Gαqi9-mtAEQ (B) in 
response to 0.1 % triton-X-100 
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4.4 Summary and conclusions 
With HEC-1B-hY5 cells stably expressing the hY5R a starting point was given to develop 
functional fluorescence- and bioluminescence-based Ca2+ assays. Therefore, the suitability of 
chimeric G proteins such as Gαqi5 was investigated for their ability to redirect receptor 
signaling to the PLCβ pathway. By modification of a C-terminal amino acid by PCR, yielding 
Gαqi9 a benefit effect concerning receptor coupling was expected. Initially, transfection with 
the chimeric G protein Gαqi5 resulted in robust intracellular Ca2+ mobilization detected in a 
flow cytometric calcium assay with Fluo-4 loaded cells. The signal was receptor mediated as 
it could be blocked by the Y5R selective antagonist CGP 71683A and a concentration 
response curve could be constructed yielding an EC50 in accordance with data reported in 
literature. Unfortunately, the expression of the chimeric G protein was not stable and the Ca2+ 
signal diminished after several passages of the cells. Further transfection experiments with 
Gαqi5 respectively Gαqi9 did not fulfil the expectations in terms of robust signals and high 
signal-to-noise ratios (especially regarding low pNPY concentrations) in flow cytometric 
(Fluo-4) or spectrofluorimetric (Fura-2) assays, irrespective of the number of passages of the 
parent HEC-1B-hY5 cells. Thus, declining levels of receptor expression due to senescent cells 
are unlikely. Nevertheless, HEC-1B-hY5-Gαqi5/9 cells were further transfected with the 
pcDNA3.1/Zeo-mtAEQ to test the ability of these cells to express functionally active 
aequorin. Indeed, luminescence was measured, when co-transfected HEC-1B-hY5-Gαqi9 cells 
were treated with triton-X-100. However, compared to assays established for the hY2R and 
the hY4R this signal amounted to only about 4 % of the expected value. Nevertheless, 
optimizations in the generation and selection of stable HEC-1B-hY5 transfectants might pave 
the way for versatile functional calcium assays. 
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Chapter 5 
 
 
5 Establishment of a steady-state GTPase assay for the 
human NPY Y2 receptor 
 
5.1 Introduction 
5.1.1 Functional assays for the NPY Y2 receptor 
As the Y2 receptor is known to couple to Gi/o proteins (Michel et al., 1998), initially, 
radiochemical assays based on the inhibition of forskolin-induced cAMP formation (Beck-
Sickinger et al., 1992; Goumain et al., 2001) were devised. Later, assay formats more suitable 
for high throughput screening (HTS) were developed. For example, the need for 
prestimulation of the cells by forskolin was eluded by redirecting GPCR signaling to the PLC 
pathway via chimeric G proteins. Thus, receptor activation leads to an elevation of 
intracellular calcium, which is measured by Ca2+ chelating fluorescent probes (Dautzenberg et 
al., 2005; Ziemek, 2006). Additionally, quantification of formation of tritiated IP3 was applied 
(Berridge, 1983; Merten et al., 2007) and a luminescence-based assay was developed by 
Ziemek (Ziemek et al., 2006). Very recently, Brothers et al. (Brothers et al., 2010) reported 
on a cAMP biosensor assay, which was applied for ligand screening at the hY2R. For this 
purpose, HEK293 cells, stably expressing a cyclic nucleotide-gated channel (CNG) together 
with the hY2R and a membrane potential sensitive fluorescent indicator were used to measure 
the polarization state of the cell membrane. Aiming at ultra HTS, complex industrial 
instrumentation is required, which is not ideal for laboratory research. Most of the mentioned 
functional assays are costly, laborious and time consuming, especially when, for example, 
cells have to be stably transfected, cell lines maintained at a given protein expression level or 
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membranes be prepared from mammalian cells, e.g. for GTPγS binding (Dautzenberg et al., 
2005). Given the advantages of the steady-state GTPase assay mentioned in section 1.3.3, 
especially regarding Gi/o coupled receptors, the baculovirus/Sf9 cell system was exploited for 
the hY2R. 
 
5.1.2 Coupling of the NPY Y2 receptor to Gi/o proteins 
High coupling efficiency of the GPCR to the preferred G protein should result in robust 
stimulation and favourable signal-to-noise ratio in a steady-state GTPase assay. According to 
literature G protein coupling has been investigated, both in native cells endogenously 
expressing hY2Rs and in recombinant systems, giving contradictory results concerning G 
protein selectivity. For example, in SMS-KAN cells the hY2R conveys signals predominantly 
via Gαi3, but not Gαo (Freitag et al., 1995), while a knockdown of Gαi2 in renal proximal 
tubular cells is sufficient to abolish PYY-mediated effects (Voisin et al., 1996a; Voisin et al., 
1996b) and purified Gαo protein mediates NPY effects, when infused into sensory neurons 
(Ewald et al., 1988). The hY2R was also reported to elevate intracellular calcium levels in 
transfected HEK293 cells (Gerald et al., 1995). Recently, Misra et al (Misra et al., 2004) co-
expressed Y1R, Y2R, and Y4R in smooth muscle cells and found that all three receptors 
preferentially coupled to Gαi2, while the Y2R and the Y4R additionally activated Gαq. 
However, coupling to Gαo in this cell line has not been investigated. As the hY2R is largely 
expressed in the central nervous system with Gαo being the major neuronal G protein 
(Birnbaumer et al., 1990), coupling of the receptor to this G protein is also of interest. Thus, 
in this work, the receptors were combined with the physiologically most prevalent 
representatives of the family of Gi/o proteins in the Sf9 cell expression system. 
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5.2 Materials and Methods 
5.2.1 Preparation of the SF-hY2-His6 construct by sequential overlap 
extension PCR 
In order to direct the receptor towards the cell membrane the cDNA of the hY2R was 5’ 
terminally tagged with the cleavable signal peptide from influenza hemagglutinin flanked by 
the FLAG epitope, which is recognized by the M1 antibody. The sequence for the 
hexahistidine was attached at the C-terminus of the receptor for analytical purposes, for 
purification and to improve proteolytic stability. These modifications were generated by 
sequential overlap extension PCR in three steps (Fig. 5.1). In PCR 1a, the DNA sequence of 
the signal peptide (S) and the FLAG epitope (F) was amplified. A plasmid containing the SF 
sequence was used as template, the sense pGEM primer, which starts 5’ of the SacI site of the 
pGEM-3Z plasmid and an antisense primer encoding the final part of the FLAG sequence 
followed by the start codon of the receptor. In PCR 1b, the cDNA of the receptor was 
amplified using pcDNA3-hY2 as template. PCR 1b was performed with the sense primer 
FLAG-hY2R-sense encoding a C-terminal part of FLAG followed by the first 21 bp of the 
starting sequence for the receptor and an antisense primer 6His-hY2-as comprising 18 bp of 
the C-terminal sequence of the receptor, followed by His6, the stop codon and the XbaI 
restriction site. The two products from PCR 1a and 1b served as templates in PCR 2. The 
sense pGEM primer and the 6His-hY2-as primer were used to generate the gene construct of 
SacI restriction site followed by the signal sequence, the FLAG epitope, the hY2R DNA, the 
hexahistidine tag, the stop codon and an XbaI restriction site.  
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Fig. 5.1: Strategy for the construction of the insert SF-hY2-His6 by overlap extension PCR 
Three sequential PCRs are required to tag the hY2 receptor cDNA N-terminally with the signal and FLAG and 
C-terminally with the 6His sequences and to introduce the restriction sites for cloning. The template for PCR 2 
are the products from the preceding PCRs annealing at the C-terminal FLAG sequence and the start codon 
(ATG) of the receptor. The stop codon (TAA) is shifted C-terminally behind the 6His-tag. Arrows represent 
primers. Angulate arrows bear the introduced sequences and do not anneal with templates in those regions. For 
further explanations see the text above. 
SacI Signal FLAG hH4 
pGEM-3Z-SF-hH4 
SacI Signal FLAG ATG 
PCR 1a: 
PCR 1b: 
hY2 
pcDNA3-hY2 
FLAG hY2 6His XbaI ATG 
PCR 2: 
TAA 
SacI Signal FLAG ATG 
FLAG hY2 6His XbaI ATG TAA 
SacI Signal FLAG ATG hY2 6His TAA XbaI 
PCR 1a product 
PCR 1b product 
PCR 1a product 
PCR 1b product 
PCR 2 product 
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5.2.1.1 PCR 1a for the hY2R 
In PCR 1a the cDNA containing the sequences for the SacI restriction site and the SF 
followed by the start codon ATG were amplified using 100 ng of the plasmid pGEM-3Z-SF-
hH4-His6, kindly provided by Dr. E. Schneider (Dept. of Pharmacology, University of 
Regensburg, Germany), as template. The primers were obtained from MWG (Ebersberg, 
Germany). 
 
sense pGEM   5’-GCT CAC TCA TTA GGC ACC-3’ 
antisense pGEM  5’-CAT GGC GTC ATC ATC GTC-3’ 
 
All other reagents were from Fermentas Life Sciences (St. Leon-Rot, Germany), if not stated 
otherwise. PCR reaction mixtures contained 2.5 U of recombinant Pfu DNA Polymerase, 10 
µl of  10x Pfu buffer, 3.5 mM MgSO4, dNTP Mix (0.2 mM each), primers (0.5 µM each) and 
water up to a volume of 100 µl. PCR 1a was performed without (Fig. 5.2 A) or with 
(Fig. 5.2 B) 10 % DMSO to prevent annealing of template cDNA. PCR reactions were 
performed in a Mastercycle gradient Thermocycler (Eppendorf, Hamburg, Germany). 
 
Cycling parameters were: 
(1) initial denaturation 95 °C, 3 min 
(2) denaturation  95 °C, 1 min 
(3) annealing  55 °C, 2 min 
(4) extension  72 °C, 2 min 
(5) final extension  72 °C, 5 min 
(6) hold       4 °C 
Steps (2) to (4) were repeated 24 times. 
 
The product of PCR 1a was expected to 
have 282 bp. As shown in the 1 % agarose 
gel in Fig. 5.2 the band lies right above 
the 300 bp of the DNA ladder. 
Nucleotides and polymerase were 
removed and the PCR product desalted with the QIAquick PCR Purification Kit (Qiagen). 
The concentrations were estimated relative to the standard to 10 to 20 ng/µl (Fig. 5.2). 
 
1500 
500 
B
Fig. 5.2: Agarose gel electrophoresis of PCR 1a 
product, (A) without and (B) with DMSO 10 % 
in PCR reaction mixtures; Numbers indicate the 
sizes of bands in the DNA ladder in base pairs 
(bp). 
A
1500 
500 
200 300 
200 
300 
282 282 
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5.2.1.2 PCR 1b for the hY2R 
In PCR 1b, the cDNA of the receptor was amplified using pcDNA3-hY2 as template. The 
vector pcDNA3-hY2 was prepared by R. Ziemek (Ziemek, 2006), hY2 sequence 
corresponding to the published sequence with the GenBank accession no. U32500 (Rose et 
al., 1995). The receptor sequence was extended N-terminally by a part of the FLAG 
sequence and C-terminally by a hexahistidine tag followed by the shifted stop codon and the 
XbaI restriction site. These modifications were introduced via the primer pairs used at a final 
concentration of 0.5 µM each. 
 
FLAG-hY2R-sense 5’-AAG GAC GAT GAT GAC GCC ATG GGT CCA ATA 
GGT GCA GAG-3’  
6His-hY2-as 5’-GG TCC TCT AGA TTA GTG ATG GTG ATG ATG GTG 
GAC ATT GGT AGC CTC TGT-3’ 
 
Reaction mixtures were adjusted to a volume of 50 µl containing 1 U of PhusionTM High-
Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) with 10 µl of either 5x 
PhusionTM HF buffer or 5x PhusionTM GC, dNTPs 0.2 mM each, 10 ng of template DNA, 
primers 0.5 µM each and DMSO 3%.  
 
PCR reactions were conducted with a temperature gradient at 6 different temperatures as 
follows:  
(1) initial denaturation  98 °C, 30 s   
(2) denaturation  98 °C, 10 s 
(3) annealing  62 °C, 30 s 
(4) Gradient  10 °C, R=3 °C/s 
(5) extension  72 °C, 21 s 
(6) final extension  72 °C, 7 min 
(7) hold      4 °C   
Steps (2) to (5) were repeated 25 times. 
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Fig. 5.3 shows the expected products from PCR 1b for hY2R at 1188 bp on a 1.5 % agarose 
gel. Both buffer systems, HF and GC (for GC rich DNA templates) are suitable for this PCR 
reaction, with the GC buffer yielding a higher amount 
of product. By products are found at ≈100 bp at all 
temperatures, however HF buffer and higher 
temperatures show less side bands (Fig. 5.3 A). All 
PCR preparations were pooled and purified with the 
QIAquick PCR Purification Kit without further 
separation from side products by gel electrophoresis. 
DNA concentration of the PCR 1b product amounted 
to ≈12 ng/µl (Fig. 5.4). 
 
5.2.1.3 PCR 2 for the  hY2R 
The annealed products of PCR 1a and PCR 1b served as the template (5 or 10 ng each, cf. 
Fig. 5.5) for the amplification of the new insert SF-hY2R-His6 flanked by the restriction sites 
SacI (at the 5’ end) and XbaI (at the 3’ end) in PCR 2 (cf. Fig. 5.1). The sense primer from 
PCR 1a (sense pGEM) and the antisense primer from PCR 1b (6His-hY2-as) were used at a 
concentration of 0.5 µM each. All other reagents were used by analogy with 5.2.1.2 with the 
exception that only the 5x PhusionTM HF buffer was applied. Cycling conditions were the 
A 
°C     52    53.5  57.5  62.8  68    71.6
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Fig. 5.3: Agarose gel electro-
phoresis of PCR 1b product for 
hY2 performed with PhusionTM HF 
buffer (A) or with PhusionTM GC 
buffer (B) at different tempera-
tures as indicated for each lane 
100 
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1500 1188 
1188 
Fig. 5.4: Agarose (1.5 %) gel electro-
phoresis of purified PCR 1b product for 
the estimation of DNA concentration 
500 
1500 1188 
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same as for PCR 1b, but reactions were performed only at the four highest temperatures as 
indicated at the bottom of each lane in Fig. 5.5. 
  
Agarose gel (1.5 %) electrophoresis showed comparable results for all conditions (Fig. 5.5). 
Expected bands with the size of 1454 bp were present in all PCR preparations, the same holds 
for side products of ≈350 bp. All products were pooled and purified with the QIAquick PCR 
Purification Kit. The DNA concentration of the insert SF-hY2-His6, (ca. 10 ng/µl) was 
estimated from the intensities of the bands relative to the DNA standard. 
 
5.2.2 Subcloning of SF-hY2-His6 into pGEM-3Z 
The SF-hY2R-His6 fragment was subcloned into a pGEM-3Z plasmid containing the 
restriction sites SacI and XbaI in its multiple cloning site. After transformation and 
amplification in E. coli Top10 cells, the fragment from pGEM-3Z-SF-hY2R-His6 was 
subcloned into a baculovirus expression vector pVL1392 containing the same restriction sites 
in its multiple cloning site (see 5.2.3). 
500 ng of the previously prepared  pGEM-3Z-SF-hY4-His6 plasmid were digested with 10 U 
of SacI (MBI Fermentas, St. Leon Rot, Germany) and 10 U of XbaI (MBI Fermentas) in a 
reaction mixture containing 2 µl of 10x TangoTM buffer (MBI Fermentas) in a final volume of 
20 µl for 2 h at 37 °C. To prevent self ligation the plasmid was dephosphorylated by 
incubation with 0.04 U of calf intestinal phosphorylase (CIP, Boehringer Mannheim, 
Mannheim, Germany) for 1 h at 37 °C. Subsequently, CIP was inactivated by heating at 80 °C 
for 20 min. The eluate from PCR 2 obtained with the QIAquick PCR Purification Kit 
(~ 348 ng) was digested with SacI and XbaI (10 U each) in 1x TangoTM buffer for 2 h at 37 
   57.5     62.8     68      71.6                 °C        57.5     62.8       68      71.6 
A B 100 
500 
1500 
Fig. 5.5: Agarose gel electrophoresis of the products from PCR 2 with 5 ng of 
template DNA (A) and 10 ng of template DNA (B); Annealing temperatures are 
indicated at the bottom of each lane. 
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°C. Thereafter, the digested DNA fragments were separated by agarose gel electrophoresis, 
and DNA was estimated by comparing the intensities of DNA fragments with those from 
bands in the DNA ladder of approximately the same size.  
After extraction from the gel, ligation was performed with a tenfold molar excess of SF-hY2-
His6 in a reaction mixture containing 5 U of T4 DNA Ligase (MBI Fermentas) and 1x 
Ligation buffer (MBI Fermentas) at room temperature overnight. The next day the sample 
was used for transformation. 
Mini-Preps were prepared with colonies 
picked from ampicillin containing agar 
plates and plasmid DNA was analyzed by 
restriction enzyme digestion with SacI and 
XbaI. A positive clone was chosen for 
Maxi-Prep. After double digestion with the 
same enzymes, expected bands were found 
in gel electrophoresis (insert 1293 bp and 
plasmide 2734 bp, Fig. 5.6). Sequencing 
with the SP6 and the T7 standard primers 
revealed a conservative mutation (A vs. G, 
in position 42 from the start codon) in the 
signal peptide sequence.  
 
5.2.3 Subcloning of SF-hY2-His6 into pVL1392 
Subcloning of the construct into the pVL-1392 vector was essentially carried out as described 
in 5.2.2. The insert was excised from the plasmid pGEM-3Z-SF-hY2-His6 with SacI and XbaI. 
The previously prepared pVL-1392-SF-hY4-His6 was digested in the same way and 
dephosphorylated with 0.02 U of CIP. Ligation was performed at five-, ten- and twentyfold 
molar excess of insert to plasmid, and used for transformation. Minipreps were assessed for 
the existence of the XhoI restriction site, which is important for the following homologous 
recombination of the pVL1392 vector with the baculovirus DNA to form intact baculoviruses 
(section 1.3.3). For this purpose, plasmid preparations were double digested with XbaI and 
XhoI to yield fragments of 3535 bp and 7425 bp (Fig. 5.7). After Maxiprep with clone 52 the 
same silent mutation A42G (counted from the ATG of the signal peptide) as in the insert in 
pGEM-3Z was detected by sequencing.  
Fig. 5.6: Restriction analysis of the 
Maxiprep of pGEM3Z-SF-hY2-His6 with 
SacI and XbaI; The insert (1293 bp) and 
the linearized plasmid (2734 bp) were 
found to have the correct sizes. 
1500 
3000 
1293 
2734 
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5.2.4 Sf9 cell culture 
Sf9 cells were cultured in SF 900 II medium (Invitrogen, Carlsbad, USA), supplemented with 
fetal calf serum (Biochrom, Berlin, Germany) to 5 % (v/v) and gentamicin sulfate (0.1 mg/ml, 
Cambrex Bio Science, Walkersville, MD) in 250 ml disposable Erlenmeyer flasks at 28 °C at 
125 rpm in an incubation shaker (New Brunswick Scientific, model C24KC, Edison, NJ). Sf9 
cells were maintained at a density of 0.5 to 6.0 · 106 cells/ml. 
 
5.2.5 Generation of recombinant baculoviruses 
Recombinant baculoviruses, encoding the FLAG- and hexahistidine-tagged hY2 and hY4 
receptors, were generated using the BaculoGOLD transfection kit (PharMingen, San Diego, 
CA) according to the manufacturer’s protocol. Briefly, Sf9 cells (3 ml) were seeded in 25 cm2 
culture flasks at a density of 1.3 · 106 cells/ml and were allowed to attach. For initial 
transfection, 5 µg of pVL-DNA were mixed with 0.45 µg of baculovirus DNA and added to 
the cells followed by an incubation of 4 h at 28 °C. Thereafter, transfection buffer was 
removed by suction, cells were washed and incubated in fresh medium (3 ml) for 7 days at 
28 °C. To obtain high-titer virus stocks 1 ml of the supernatant (after centrifugation under 
sterile conditions) was used to infect Sf9 cells suspended in 50 ml medium in a 125 ml 
Erlenmeyer flask and the culture was incubated one week at 28 °C and 125 rpm. As a control 
for infectious viruses, 3 ml of this culture were transferred into a 25 cm2 flask and kept at 
XhoI - 1901
SacI – 4153
XbaI – 5436
Fig. 5.7: Vector map of pVL1392-SF-hY2-His6 with given restriction sites XhoI, SacI and XbaI (A) and 
restriction enzyme digestion of the Minipreps from the different ligation samples (numbers of clones given 
below each lane) with XhoI and XbaI (B) 
A B 
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28 °C in parallel. After one week of incubation, the release of baculoviruses in the 25 cm2 
control flask was confirmed microscopically, becoming obvious by the lysis of the cells. The 
cell debris was removed by centrifugation in a sterile 50 ml Falcon tube at 1,500 g and the 
supernatant (first amplification) was kept protected from light at 4 °C. In a second 
amplification step, cells seeded at 3.0 · 106 cells/ml in a 100 ml culture (250 ml Erlenmeyer 
flask) were infected with 5 ml of the supernatant from the first amplification and incubated for 
48 h. The supernatant was harvested under sterile conditions and kept under protection from 
light at 4 °C. After the 48 h culture period, cells showed signs of infection (e.g. altered 
morphology, viral inclusion bodies) but most of them were still intact. For membrane 
preparation this high-titer virus stock was used to infect Sf9 cells at a ratio of 1:100. 
Baculoviruses Gαi1, Gαi2 and Gαi3 were gifts from Dr. A. G. Gilman (Dept. of Pharmacology, 
University of Southwestern Medical Center, Dallas, TX), whereas baculovirus encoding rat 
Gαo1 was donated by Dr. J. C. Garrison (University of Virginia, Charlottesville, VA). 
Recombinant baculovirus encoding the Gβ1γ2 subunits was a kind gift of Dr. P. Gierschik 
(Dept. of Pharmacology and Toxicology, University of Ulm, Germany). Baculoviruses 
encoding RGS4 and GAIP were a kind gift from Dr. E. Ross (University of Texas 
Southwestern Medical Center, Dallas, TX). 
 
5.2.6 Membrane preparation and determination of protein concentration 
For membrane preparation buffers were prepared from following stock solutions which were 
pH adjusted, sterile filtered and stored at 4 °C or -20 °C (in case of protease inhibitors) until 
use: 
10x PBS: 27 mM KCl, 15 mM KH2PO4, 81 mM Na2HPO4 and 1.37 M NaCl (all chemicals 
from Merck, Darmstadt, Germany) at pH 7.4 in millipore water 
1 M Tris·HCl (usb, Staufen, Germany) adjusted to pH 7.4 
0.5 M EDTA (Merck) adjusted to pH 7.4 
Protease inhibitors: benzamide (Sigma, Deisenhofen, Germany) and leupeptin (Merck) 
1 mg/ml in millipore water and PMSF 200 mM in isopropyl alcohol, all stored at -20 °C. 
10x binding buffer: 750 mM Tris base (usb), 10 mM EDTA (Merck) and 125 mM MgCl2 
(Merck) adjusted to pH 7.4. 
On the day of membrane preparation the following buffers were prepared: 
PBS buffer 
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Lysis buffer: 10 mM Tris·HCl , 1 mM EDTA, 10 µg/ml benzamide , 10 µg/ml leupeptin  and 
200 µM PMSF. 
Binding buffer. 
For membrane sets 30 ml culture of 3.0 · 106 cells/ml in fresh medium were infected 1:100 
with up to four different high-titer virus stocks, to combine receptors with G proteins and 
RGS proteins (cf. section 5.3.1) in 100 ml disposable Erlenmeyer flasks. All membrane 
preparation steps were conducted at 4 °C or on ice in 50 ml Falcon tubes. After incubation for 
48 h, Sf9 cells were checked for signs of infection and harvested by centrifugation at 170 g 
for 10 min. The cells were re-suspended in the same volume of PBS with disposable 3 ml PE 
Pasteur pipettes (VWR, Darmstadt, Germany) and centrifuged again. The pellet was 
suspended in 10 ml of lysis buffer and cells were homogenised in a 15 ml Dounce 
homogenizer with 25 strokes. After 5 min centrifugation at 45 g, the loose pellet contained 
nuclei and residual cells. The supernatant with the membranes was carefully pipetted into a 
Sorvall tube. Membranes were spun down at 38,500 g for 20 min in a Sorvall RC-5B 
centrifuge, resuspended in fresh lysis buffer and the centrifugation step was repeated. After 
discarding the supernatant, the membrane pellet was suspended in 15 ml of binding buffer and 
homogenized with a 20 ml syringe equipped with a 0.9 mm (i. d.) cannula by 15 strokes. The 
membrane suspension was aliquoted into 15 tubes (1 ml each) and stored at -80 °C until use. 
To study the effect of N-glycosylation on receptor structure and function, membranes were 
prepared from infected Sf9 cells grown in the absence and presence of tunicamycin (Sigma), 
an inhibitor of the GlcNAc-1P-transferase, at a final concentration of 10 µg/ml. The stock 
solution of tunicamycin (5 mg/ml) was prepared in 10 mM NaOH and stored at -20 °C until 
use. 
To simulate the conditions of the steady-state GTPase assay, samples were frozen and thawn 
before using the Lowry based DC Protein Assay kit (BioRad, München, Germany) according 
to the manufacturer’s instructions. 
 
5.2.7 SDS Page and immunoblot analysis 
Twofold concentrated sample buffer was prepared by dissolving 28.8 g of urea (Merck) in 
20 ml of millipore water under heating. The solution was let to cool down to room 
temperature, and SDS (1.5 g, Sigma), DTT (1.8 g), 1.5 ml of Tris·HCl, pH 8.0 (1 M), 6.0 ml 
of glycerol (50 %, Merck) and 6.0 mg of bromphenol blue (Sigma) were added and dissolved. 
The sample buffer was aliquoted in 1.5 ml tubes and stored at -20 °C until use. 
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For SDS-PAGE membranes were thawn and centrifuged at 16,100 g and 4 °C for 10 min. The 
pellets were homogenized with a syringe (equipped with a 0.4 mm cannula) by 30 strokes in a 
volume of 10 mM Tris (pH 8.0) to a final protein concentration of 2 µg/µl. Subsequently, the 
equal volume of twofold concentrated sample buffer was added and mixed with the syringe 
by 3 strokes. Samples were stored at -80 °C. 
For polyacrylamide gels and Western blotting buffers were prepared as follows: 
Buffer A: 1.5 M Tris·HCl (pH  8.8) and 0.4 % (w/v) SDS 
Buffer B: 0.5 M Tris·HCl (pH 6.8) and 0.4 % (w/v) SDS 
APS 10 %: 1 g of ammonium peroxodisulfate (APS, Serva, Heidelberg, Germany) in 10 ml 
of millipore water, aliquoted to volumes of 100 µl each and stored at -20 °C 
10x running buffer: 30 g of Tris base, 144 g of glycine (Merck) and 10 g of SDS were 
dissolved in 1000 ml of millipore water, pH was adjusted to 8.3 with concentrated HCl 
Blotting buffer (always prepared freshly before use): 14 g of glycine and 3 g of Tris base 
were dissolved in 800 ml millipore water and mixed with 200 ml of methanol 
10x TBS buffer (pH 7.6): 80 g of NaCl (VWR International, Haasrode, Belgium) were 
dissolved in 200 ml of Tris·HCl (1 M, pH 7.6) and millipore water to a volume of 1000 ml. 
The buffer was diluted 1:10 and 1000 µl/l of Tween 20 (Carl Roth GmbH, Karlsruhe, 
Germany) was added before use (TBS-T buffer). 
5 % fat-free milk (always prepared freshly before use): 5 g of fat-free milk powder were 
dissolved in TBS-T buffer. 
12 % separation gel mixtures contained 4.4 ml of millipore water, 4 ml of buffer A, 1.06 ml of 
glycerol (50 %) and 6.4 ml of acrylamide/bisacrylamide (30 % solution, acrylamide/bis-
acrylamide = 29/1, Sigma) calculated for 2 gels. Polymerization was started by addition of 
6.7 μL of N,N,N',N'-tetramethylethylenediamine (TEMED, Serva) and 66.7 μL of APS 
(10 %). The mixture was filled into gel chambers (10 x 10 x 0.8 cm) and covered with a layer 
of water-saturated isobutyl alcohol (Merck). After 45 min the gel was completely polymerized 
and the stacking gel was pipetted on top of the separation gel after the isobutyl alcohol had 
been washed away with water. Stacking gel (3 %) mixtures contained 6.5 - of millipore water, 
2.5 ml of buffer B and 1 ml of acrylamide/bisacrylamide (30 %, see above). Polymerization 
was initiated by addition of 6.7 μL of TEMED and 100 μL of APS (10 %). 
After loading the gel pockets with samples (10 µl) or 10 µl of the Prestained Protein 
Molecular Weight Marker #SM0441 (MBI Fermentas), , electrophoresis was performed in a 
PerfectBlueTM Double gel system Twin S (Peqlab, Erlangen, Germany) at 150 V for 1 – 1.5 h 
with the electrode chambers filled with running buffer.  
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Western blotting was achieved in a Perfect-Blue “Semi-Dry” electro blot apparatus (Peqlab) 
by placing the gels on top of a nitrocellulose membrane (0.2 μm, Peqlab) between 6 filter 
slides equilibrated in blotting buffer and blotted for 45 min at 250 mA. Then, the membrane 
was blocked by shaking for 2 h in fat-free milk (5 %). The membrane was washed twice for 5 
- 10 min with TBS-T buffer and then incubated overnight with the primary antibody in a 
50 ml Falcon tube under rotation (4 rpm). Primary antibodies were diluted (see Table 5.1) 
with TBS-T buffer containing 3 % BSA (VWR International) and 0.05 % sodium azide 
(Merck). The dilutions were kept at 4 °C and re-used (usually one year). The next day, 
membranes were washed three times for 15 min with TBS-T buffer and subsequently 
incubated with the secondary antibody for 1 h at room temperature. The secondary antibody, 
conjugated with horseradish peroxidase (see Table 5.1), was freshly diluted with fat-free milk 
(5 %). Then, washing was repeated and immunoreactive bands were visualized by enhanced 
chemoluminescence with the Pierce® ECL Western blotting substrate (Thermo Fisher 
Scientific, Bonn, Germany) according to the manufacturer’s protocol.   
 
Table 5.1: Overview of antibodies used for Western blot analysis of Sf9 membranes 
Primary antibody Dilution Secondary antibody Dilution 
M1 (= anti-FLAG)1 1 : 1,000 Anti-mouse (goat)1 1 : 2,000 
Anti-Gαcommon (AS 398/9)2 1 : 500 Anti-rabbit (donkey)5 1 : 10,000 
Anti-Gαi1/23 1 : 1,000 Anti-rabbit5 1 : 10,000 
Anti-Gαo3 1 : 1,000 Anti-rabbit5 1 : 10,000 
Anti-Gβcommon (AS 266)2 1 : 1,200 Anti-rabbit5 1 : 10,000 
Anti-RGS44 1 : 500 Anti-goat (donkey)5 1 : 5,000 
Anti-GAIP4 1 : 500 Anti-goat5 1 : 5,000 
1from Sigma (Taufkirchen, Germany), 2kindly provided by Dr. B. Nürnberg (Dept. of Biochemistry, University 
of Düsseldorf, Germany), 3from Calbiochem (Bad Soden, Germany), 4from Santa Cruz Biotechnology 
(Heidelberg, Germany), 5from Amersham Biosciences (München, Germany). 
 
The immunoblots were scanned with a calibrated GS-710 imaging densitometer (Bio-Rad 
Laboratories, München, Germany). Quantity One 4.0.3 software (Bio-Rad) was used for the 
analysis of band intensities. 
For the estimation of receptor and G protein expression levels a standard Sf9 membrane, 
containing the FLAG-tagged human β2-adrenoreceptor (FLAG-hβ2-AR), and purified Gαi2- 
and Gαo2 proteins were used at appropriate dilutions. The standard membrane expressing 
7.5 pmol/mg FLAG-hβ2-AR was kindly provided by the institute of pharmacology, University 
of Regensburg. The expression level was determined by radioligand binding with 
[3H]-dihydroalprenolol. 
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5.2.8 Y2 receptor antagonists 
The Y2 receptor antagonists BIIE 0246 (1) and the structural analogs 2-5 were synthesized in 
our work group by A. Brennauer and were used as solutions in DMSO 50 %. 
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Fig. 5.8: Y2 receptor antagonists used for GTPase assay validation 
 
5.2.9 Steady-state GTPase assay 
[γ-32P]-GTP was prepared in our laboratory using GDP and [32P]-orthophosphoric acid (150 
mCi/ml, obtained from PerkinElmer, Pfaffenhofen, Germany) according to a previously 
described enzymatic labelling procedure (Walseth and Johnson, 1979). 
Stock solutions and reagents for the steady-state GTPase assay were prepared as follows: 
10 mM Tris·HCl (pH 7.4) 
20 mM Tris·HCl (pH 7.4) 
1 M Tris·HCl (pH 7.4), sterile filtered 
10 mM EDTA (pH 7.4) 
100 mM MgCl2 
10 mM adenosine triphosphate (ATP, Roche, Mannheim, Germany): aliquoted to 1 ml and 
stored at –20 °C 
10 µM guanosine triphosphate (GTP, Roche): aliquoted to 1 ml and stored at –20 °C 
10 mM adenylyl imidodiphosphate (AppNHp, Roche): aliquoted to 1 ml and stored at  
–20 °C 
6.7 % (w/v) bovine serum albumin (BSA, VWR International) 
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Creatinin kinase / creatine phosphate (CK, Sigma / CP, Roche): 1 mg CK, 30 mg CP and 
15 µl of BSA 6.7% ad 1000 µl with millipore water 
Slurry: 50 g of activated charcoal (Merck) and 50 ml of 1 M NaH2PO4 (pH 2; Merck) ad 
1000 ml with millipore water, stored at 4 °C 
If not stated otherwise, stocks were stored at room temperature. 
Steady-state GTPase assays were performed for hY2R and hY4R in analogy. Following 
descriptions relate to both receptors, differences are indicated. 
For experiments regarding sensitivity of hY2/4Rs towards monovalent salts (cf. sections 5.3.3 
and 6.3.3) a dilution series of 20x concentrated salt solutions were prepared out of freshly 
prepared 3 M stocks of LiCl, LiBr, LiI, NaCl, NaBr, NaI, KCl, KBr, KI (salts obtained from 
Merck or Fluka). 
Steady-state GTPase assays were essentially performed as previously described (Preuss et al., 
2007). 
Briefly, 10 µl of 10x concentrated ligand dilution or solvent were pipetted into assay tubes. 
For experiments regarding sensitivity of hY2/4Rs towards monovalent salts (cf. sections 5.3.3 
and 6.3.3), 20x concentrated ligand and salt solutions (5 µl each) were applied, respectively. 
Then, reaction mixture containing 100 mM Tris·HCl, 200 µM EDTA, 2 mM MgCl2, 200 µM 
ATP, 200 nM GTP, 200 µM AppNHp, 0.4 % BSA, 2 µg of CK and 2.4 mM CP was prepared 
from stock solutions and pipetted 50 µl per assay tube. For experiments run in the antagonist 
mode, the reaction mixture additionally contained 100 nM pNPY (for hY2R) or 100 nM hPP 
(for hY4R). Membranes were thawn, sedimented by centrifugation at 16,100 g at 4 °C and 
sequentially homogenized with syringes, equipped with hollow needles of 0.7 and 0.4 mm 
i. d., respectively, in 10 mM Tris·HCl, pH 7.4. The membrane suspension was then pipetted 
20 µl/tube (i.e. usually 10 µg protein/tube). 
[γ-32P]-GTP (calculated as 0.1 µCi/tube) was added to 20 mM Tris·HCl (the volume 
calculated as 20 µl/tube) and stored on ice. Then, assay tubes were pre-incubated for 2 min 
each in a heating unit. Reactions were started by addition of [γ-32P]-GTP (20 µl/tube) and 
proceeded for 20 min at 25 - 27 °C, until 900 µl of slurry was pipetted for termination. 
Nucleotides are adsorbed to charcoal, but not 32Pi. After centrifugation of the samples at 
16,100 g and 4 °C, 600 µl of the supernatant were transferred into scintillation vials filled 
with 3 ml of water, and Cherenkov radiation was measured in a TRI-CARB 2800 TR liquid 
scintillation analyzer (PerkinElmer, Rodgau, Germany). 
To consider spontaneous hydrolysis of [γ-32P]-GTP, samples containing an excess of GTP 
(1 mM) instead of ligand were incubated in parallel. GTP competes with the binding of 
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[γ-32P]-GTP and thereby inhibits the enzymatic degradation of the labeled nucleotide by 
G proteins. Spontaneous hydrolysis (blank) amounted to < 1 %. The chosen conditions 
ensured that no more than 10 % of the total amount added of [γ-32P]-GTP was consumed. 
GTPase activities (as pmol Pi released per mg of protein per minute) of membranes were 
calculated according to the following equation: 
 
( ) [ ]11 min
min
67.1 −− ⋅⋅⋅⋅
⋅⋅−= mgpmol
incubationproteinmgtotalcpm
GTPunlabeledpmolblankcpmreactioncpmactivtyGTPase
 
Equation 1 
 
Explanations: 
cpm reaction radioactivity counted in 600 µl of samples except those with 1 
mM unlabeled GTP  
cpm blank radioactivity counted in 600 µl of samples containing 1 mM 
unlabeled GTP; spontaneous hydrolysis of [γ-32P]-GTP 
pmol unlabeled GTP absolute amount of GTP present in the assay tubes, i.e. 10 pmol  
1.67  factor accounting for the fact that only 600 µl of the 1000 µl 
samples were counted 
cpm total  counts resulting from total [γ-32P]-GTP added to each tube (no 
charcoal addition) 
mg protein amount of membrane protein present in each tube (usually 0.01 
or 0.02 mg) 
min incubation incubation period (duration of the enzymatic reaction, usually 
20 min) 
 
5.3 Results and Discussion 
5.3.1 Immunoblot analysis of membranes 
In order to study the G protein specificity of the hY2 receptor, two identical batches of a set of 
16 membranes were prepared comprising different combinations of the GPCR (hY2R) with 
different Gαi/o proteins and RGS proteins. Gα subunits were always co-expressed with Gβ1γ2. 
To keep protein expression approximately at the same level, the individual sets were prepared 
on the same day. An overview of such a set of membranes is given in Table 5.2. 
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Table 5.2: Overview of the set of membranes generated for the hY2R (SF-hY2-His6) 
Membrane 
preparation 
Receptor Gα Gβγ RGS protein Protein [µg/ml] 
B27 SF-hY2-His6 Gαi1 Gβ1γ2 - 472 ± 48 
B28 SF-hY2-His6 Gαi1 Gβ1γ2 RGS 4 604 ± 25 
B29 SF-hY2-His6 Gαi1 Gβ1γ2 GAIP 592 ± 10 
B30 SF-hY2-His6 Gαi2 Gβ1γ2 - 559 ± 26 
B31 SF-hY2-His6 Gαi2 Gβ1γ2 RGS 4 515 ± 9 
B32 SF-hY2-His6 Gαi2 Gβ1γ2 GAIP 559 ± 26 
B33 SF-hY2-His6 Gαi3 Gβ1γ2 - 582 ± 10 
B34 SF-hY2-His6 Gαi3 Gβ1γ2 RGS 4 534 ± 31 
B35 SF-hY2-His6 Gαi3 Gβ1γ2 GAIP 549 ± 28 
B36 SF-hY2-His6 Gαo1 Gβ1γ2 - 599 ± 12 
B37 SF-hY2-His6 Gαo1 Gβ1γ2 RGS 4 354 ± 13 
B38 SF-hY2-His6 Gαo1 Gβ1γ2 GAIP 210 ± 9 
B39 SF-hY2-His6 - - - 330 ± 4 
B40 SF-hY2-His6 - - RGS 4 417 ± 55 
B41 SF-hY2-His6 - - GAIP 465 ± 17 
B42 - Gαi2 Gβ1γ2 - 750 ± 9 
 
Membranes were analyzed by immunoblotting with the antibodies listed in Table 5.1. 
Receptor expression was confirmed with the M1 antibody, which recognizes the FLAG 
epitope of the tagged hY2R at its extracellular N-terminus. The predicted molecular weight of 
the hY2R is ≈43 kDa. Somewhat diffuse bands (Fig. 5.9 A) were found at ≈50 kDa, probably 
due to differently glycosylated forms of the receptor, which possesses one potential 
extracellular N-glycosylation site in its N-terminus.  
Using the anti-Gαcommon antibody, only the membranes expressing mammalian Gα proteins 
showed bands at the expected molecular weight ≈40 kDa. However, no bands within this 
range were visible for Gαi1 expressing membranes (B27 – B29) (Fig. 5.9 B). When reacted 
with the more selective antibody anti-Gαi1/2 only very slight bands for Gαi1 appeared 
(Fig. 5.9 C). Using the anti-Gαo antibody bands were only detected with the membranes B36 
– B38 (Fig. 5.9 D). In studies by Kleemann et al. (2008) and Schnell et al (2010) the authors 
observed a lower expression level for Gαi1, when compared to other mammalian G proteins of 
the Gαi/o family. This is an intrinsic property of Gαi1 heterologously expressed in Sf9 cells (cf. 
section 6.3.2) and does not affect its ability to interact effectively with GPCRs (Kleemann et 
al., 2008), which is also shown in sections 5.3.2 and 6.3.3. With the anti-Gβcommon antibody  - 
as expected - bands at ≈37 kDa became obvious (Fig. 5.9 E) and RGS proteins in RGS4 and 
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GAIP expressing membranes are seen at somewhat higher molecular weights ≈30 kDa than 
expected (≈ 23 – 24 kDa, Fig. 5.9 F-G). The varying protein expression levels among the 
membranes were probably due to handling during preparation, determination of protein 
concentration or pipetting into gel pockets. The results for the second set of membranes were 
identical (not shown). 
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The hY2R possesses one potential N-glycosylation site at its N-terminus. Therefore, the effect 
of N-glycosylation on the receptor’s molecular weight and function (cf. section 5.3.4) was 
studied in membranes prepared from infected Sf9 cells grown in the presence and absence of 
the GlcNAc-1P-transferase, tunicamycin. The M1 antibody recognized both, glycosylated and 
non glycosylated receptors. A pronounced band for the monomeric hY2R was detected at 
≈46 kDa, while dimers and oligomers were found at ≈103 kDa and higher molecular weights 
(Fig. 5.10) for membranes engineered both from cell cultures with and without tunicamycin. 
The intensities of the bands were comparable to those of the FLAG-hβ2AR at ≈57 kDa, but 
the signal was weaker in case of the tunicamycin treated membrane (lanes marked by arrows). 
A rough estimation of receptor expression levels was performed by comparison with 
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Fig. 5.9: Immunochemical detection of recombinant proteins expressed in Sf9 insect cells; 10 µg of protein 
from each membrane of set (B27 - B42) were loaded on each lane. Bands were detected with the following 
antibodies: (A) anti-FLAG, (B) anti-Gαcommon, (C) anti-Gαi1/2, (D) anti-Gαo, (E) anti-Gβcommon, (F) anti-RGS4 
and (G) anti-GAIP. Numbers on the left designate masses of marker proteins in kDa. 
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increasing protein amounts of a standard membrane expressing FLAG-hβ2AR at 7.5 pmol/mg. 
For the glycosylated hY2R a Bmax value of ≈4.9 pmol/mg was determined, while a decrease to 
≈3.4 pmol/mg was seen with tunicamycin treatment (Fig. 5.10). 
 
 
 
When isolated from mammalian tissues, for example rat hippocampus (Sheikh and Williams, 
1990), rabbit kidney (Sheikh and Williams, 1990; Sheikh et al., 1991) or porcine brain 
(Wimalawansa, 1995), N-glycosylation of the Y2 receptor usually makes up to ≈ 10 – 20 kDa, 
that is the receptor molecular weights found in these studies were ≈ 50 – 60 kDa. According 
to the above described immunoblot analyses, the hY2R expressed in Sf9 cells shows a 
molecular mass of ≈ 46 - 50 kDa, which lies in the lower range of molecular weight compared 
to literature. However, this is not surprising, because Sf9 insect cells are known to have very 
simple glycosylation patterns compared to mammalian cells (Massotte, 2003). Tunicamycin 
treatment has virtually no effect on receptor molecular weight (Fig. 5.10). However the 
expression level of receptor is lowered by ≈1.5 pmol/mg with tunicamycin, which can be 
taken as a hint to the implication of N-glycosylation in the proper folding of the receptor 
protein and/or its targeting to the membrane. 
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Fig. 5.10: Quantitative immunoblot analysis 
of two membranes expressing the hY2R from 
tunicamycin treated (lanes marked by an 
arrow) and non-treated cells with the anti-
FLAG (M1) antibody; A dilution of a 
reference membrane preparation with the 
expression of 7.5 pmol/mg hβ2AR was used 
to estimate the receptor expression level of 
the hY2. White numbers on the bottom of 
each lane indicate the amount of protein in 
µg loaded onto the gel. Expression levels for 
glycosylated hY2R were ≈4.9 pmol/mg and 
for non glycosylated ≈3.4 pmol/mg. 
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5.3.2 Coupling efficiency of the hY2R to Gαi/o proteins 
In view of the establishment of a steady-state GTPase assay with a co-expression system for 
ligand screening purposes offering high signal-to-noise ratios, the preferential G protein for 
hY2R had to be determined. Thus, with the two batches of membranes combining the hY2R 
with different Gα-subunits (always co-expressed with Gβ1γ2) the coupling efficiency of hY2R 
to Gαi/o proteins was investigated. RGS proteins, RGS4 and GAIP, were co-expressed to 
identify possible beneficial effects on signal enhancement.  
Steady-state GTPase assays were performed with 100 nM of pNPY and under control 
conditions. Thus, stimulated and basal GTPase activities were determined, and signal-to-noise 
ratios expressed in % of basal GTPase activity were calculated for each membrane. In 
Fig. 5.11 hY2R coupling to mammalian Gαi/o proteins and endogenous Sf9 insect cell G 
proteins is shown. Low basal GTPase activities are found throughout all membranes in 
comparison to the ones co-expressing Gαo. The hY2R showed stimulation in combination with 
all mammalian G proteins, but was poorly activated, when co-expressed with endogenous Sf9 
insect cell G proteins only. In fact, the hY2R co-expressed with Gαi3 and RGS4 or GAIP, 
yielded highest stimulations (≈ 290 - 310 % of basal GTPase activity in Fig. 5.11 B). 
However, robust signals were also obtained from hY2R + Gαi2 and hY2R + Gαo + RGS4 or 
GAIP. Because of the lower basal GTPase activity and the high signal-to-noise ratio further 
examinations were mainly performed with hY2R + Gαi2. Gαi2 expressed in control membranes 
exhibited no elevated GTPase activity upon stimulation with 100 nM pNPY. 
In contrast to literature, these results show that the hY2R couples with comparable efficiency 
to all Gαi proteins and also to Gαo, although to a somewhat less extent. Endogenous G proteins 
of Sf9 cells are activated only poorly by hY2Rs. Both RGS4 and GAIP enhance signaling via 
Gαi3, Gαo and endogenous G proteins. The combination hY2R + Gαi2 + Gβ1γ2 showed a high 
signal-to-noise ratio allowing the investigation of constitutive receptor activity and the 
pharmacological characterisation of ligands as full/partial agonists, neutral antagonists or 
inverse agonists and thus providing a well suited system for ligand screening. 
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5.3.3 Effects of monovalent salts on the GTPase activity 
It is well established that Na+ acts as an allosteric inverse agonist at several Gi/o-coupled 
GPCRs and stabilizes the inactive state of the receptors (Seifert and Wenzel-Seifert, 2001; 
Seifert and Wenzel-Seifert, 2002). Therefore, basal and stimulated GTP hydrolysis was 
Fig. 5.11: Comparison of the coupling efficiency of hY2R to Gαi/o proteins in the presence and absence of 
RGS4 or GAIP; The human Y2R was co-expressed with Gαi1, Gαi2, Gαi3 and Gαo1 each with Gβ1γ2 and with 
or without RGS4 or GAIP, respectively. Control membranes contained hY2R alone, hY2R in combination 
with RGS4 or GAIP and Gαi2 + Gβ1γ2. (A) Absolute GTPase activities under control conditions open bars 
(basal) and upon stimulation with 100 nM pNPY (black bars). (B) GTPase activities relative to basal 
expressed in percent. Data are means ± S.E.M. of at least 3 independent experiments performed in duplicate 
with two membrane batches prepared on one day each. 
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measured in the presence of increasing concentrations of monovalent salts, and concentration 
response curves were constructed (Fig. 5.12). 
 
Major effects become obvious for anions rather than for cations at the hY2R co-expressed 
with Gαi2 and Gβ1γ2. The concentration response curves of the chlorides (Fig. 5.12 A, D, G) 
show stable basal GTPase activity with a slight drop of stimulated GTPase activity at higher 
salt concentrations. The same is true for the bromides (Fig. 5.12 B, E, H), although the 
decrease in stimulated GTPase activity is steeper. The most pronounced effect is observed 
with the iodides (Fig. 5.12 C, F, I), where the response of activated hY2R almost equals the 
value of basal GTPase activity at a concentration of 150 mM. The Li+ salts seem to elevate 
basal GTPase activity in ascending order Cl- < Br- < I- (Fig. 5.13 A - C), whereas no 
reduction of basal GTPase activity in the presence of Na+ was observed, indicating that the 
Fig. 5.12: Basal and ligand-stimulated GTPase activity depending on the concentration of various 
monovalent salts as indicated on the abscissa; High-affinity GTPase activity was determined with a Sf9 
membrane expressing hY2R + Gαi2 + Gβ1γ2 under control conditions (○) and upon stimulation with 100 nM 
pNPY (□). Data are means ± S.E.M. of one representative experiment performed in duplicate. 
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hY2R is devoid of constitutive activity (Fig. 5.12 D - F). The same results were obtained, 
when GAIP was present in the membrane (data not shown). 
 
The effect of NaCl on hY2R was studied in combination with mammalian Gαi1, Gαi3 and Gαo, 
however no differences in concentration response curves were found (Fig. 5.13). 
  
 
5.3.4 Effect of N-glycosylation on receptor function 
According to immunoblot analyses (cf. section 5.3.1) the molecular weight of hY2R is not 
affected by treatment with the GlcNAc-1P-transferase inhibitor, tunicamycin, but the 
expression level of protein suffers a loss of ≈1.5 pmol/mg. To investigate the influence of N-
glycosylation on receptor function, steady-state GTPase assays were performed and 
concentration response curves for pNPY recorded (Fig. 5.14). After tunicamycin treatment 
the concentration-response curve was comparable to the control with untreated membranes. 
However, the maximal response was only 30 % relative to that of the control, which probably 
reflects an impaired expression in the presence of the GlcNAc phosphotransferase inhibitor. 
The determined EC50 (17.8 ± 7.3 nM) for pNPY at the tunicamycin treated membrane was in 
agreement with the EC50 (11.7 ± 3.0 nM) at control membranes. Thus, the unglycosylated 
Fig. 5.13: Basal and stimulated GTPase activity depending on the concentration of NaCl; High-affinity 
GTPase activity was determined with membranes expressing the hY2R in combination with different Gα-
subunits as indicated in titles above graph panels (always along with Gβ1γ2). Data are means ± S.E.M. of 
one representative experiment performed in duplicate. 
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receptor retains its function, however with a decreased efficacy for its physiological ligand. 
This could be due to the lower expression level as N-glycosylation probably confers to correct 
receptor folding and targeting to the membrane. 
 
 
5.3.5 Evaluation of the expression system hY2R + Gαi2 + Gβ1γ2 
For assay validation, concentration response curves of peptidergic ligands were recorded 
(Fig. 5.16 A) at membranes expressing hY2R + Gαi2 + Gβ1γ2 and EC50 values calculated. 
Furthermore, non peptidergic Y2 receptor antagonists with known affinities were tested in the 
steady-state GTPase assay by constructing inhibition curves from obtained data (Fig. 5.15 B). 
The concentration response curves yielded EC50 values of 11.7 ± 3.0 nM for pNPY, 
23.7 ± 6.2 nM for pNPY13-36 and 7.5 ± 1.2 nM for pPYY, which are in good agreement with 
data from other assay formats (Dautzenberg et al., 2005; Ziemek et al., 2006; Merten et al., 
2007). The antagonistic activities of nonpeptidergic Y2 receptor antagonists were determined 
in the presence of 50 nM pNPY. Likewise the IC50 value of 1 (64.5 ± 8.1 nM) was in good 
agreement with data from the literature (Doods et al., 1999; Dautzenberg, 2005; Ziemek et al., 
2006). There was a tendency towards higher IC50 values in the case of the BIIE 0246 
derivatives (compounds 2-5), probably due to variable assay parameters, such as the period of 
incubation and adsorption effects to materials used in the different assays. However there was 
a good correlation between the Kb values from this work and those determined in an aequorin 
Fig. 5.14: Concentration response curves of 
pNPY at hY2R, Gαi2 and Gβ1γ2 expressing 
membranes from Sf9 cells grown in the 
presence (●) and absence (○) of 
tunicamycin; Data are means ± S.E.M. 
from representative experiments performed 
in duplicate. 
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assay, established by Ziemek et al. (2006) in our work group. Pharmacological data from the 
steady-state GTPase assay are summarized in Table 5.3. 
 
 
 
 
 
5.4 Summary and conclusions 
The baculovirus Sf9 insect cell system has proven to be suitable for the functional 
reconstitution of the hY2R in combination with different Gi/o proteins. The receptor coupled 
with comparable efficiency to Gαi1, Gαi2 and Gαi3, respectively, while with Gαo the 
signal-to-noise ratio was poor. RGS proteins enhanced ligand stimulated signal in expression 
systems with Gαi3, Gαo and endogenous insect cell G proteins. The combination of hY2R and 
Gαi2 yielded a high signal-to-noise ratio and was chosen for validation with peptidergic and 
non-peptidergic ligands. Pharmacological data obtained are in good agreement with literature 
and are summerized in Table 5.3. 
 
 
 
Fig. 5.15: Concentration-response curves of peptidergic ligands (A) and inhibition curves of 
compounds 1-5 at Sf9 membranes containing hY2R, Gαi2 and Gβ1γ2 (B); Inhibition curves were 
recorded in the presence of 50 nM pNPY. Data are means ± S.E.M. from representative experiments 
performed in duplicate. 
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Table 5.3: Pharmacological data of hY2R ligands determined in the steady-state GTPase 
assay with membranes expressing the hY2R + Gαi2 + Gβ1γ2 
Peptide EC50 [nM] Emax 
pNPY 11.7 ± 3.0 (n=8) - 
pNPY (Tun) 17.8 ± 7.3 (n=3) - 
pNPY13-36 23.7 ± 6.2 (n=3) 0.94 ± 0.1 
pPYY 7.5 ± 1.2 (n=3) 1.0 ± 0.03 
Antagonist IC50 [nM] Kb [nM] 
1 64.5 ± 8.1 (n=5) 10.2 ± 1.8 
2 377.6 ± 33.8 (n=3) 71.7 ± 6.4 
3 289.4 ± 61.5 (n=3) 54.9 ± 11.7 
4 2,139 ± 261 (n=3) 406.0 ± 49.7 
5 6,079 ± 214 (n=3) 1,154 ± 41 
Mean values ± S.E.M. of at least three independent experiments performed in duplicate. Data derived from 
membranes engineered in the presence of tunicamycin are marked with (Tun). IC50 values were determined in 
the presence of 50 nM pNPY and Kb values of antagonists were calculated using the Cheng-Prusoff equation. 
 
The chosen expression system allows not only for the screening of new ligands at the hY2, but 
also renders investigations on receptor structure and function depending on N-glycosylation 
possible. Furthermore, the influence of monovalent salts on receptor function can be easily 
assessed, because in contrast to cell based assays, the salt concentration at the receptor can be 
defined exactly. Thus, with the steady-state GTPase assay for the hY2R a powerful and 
versatile tool has been established. 
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6 Establishment of a steady-state GTPase assay for the 
human NPY Y4 receptor 
 
6.1 Introduction 
Due to the common signaling of Y receptors via Gi/o proteins, the same assay formats as 
already mentioned for the Y2 receptor were essentially applied for the Y4R. For example, 
measurements of the inhibition of forskolin induced cAMP formation (Parker et al., 1998; 
Voisin et al., 2000), the accumulation of tritiated IP3 (Berridge, 1983; Merten et al., 2007) or 
the elevation of intracellular Ca2+ utilizing fluorescent probes (Dautzenberg et al., 2005) or 
bioluminescence (Ziemek et al., 2007) as well as GTPγS binding (Dautzenberg et al., 2005) 
have been reported. Besides, Chen et al. (2000) used Xenopus laevis melanophores, 
transfected with hY1/2/4R, to assess constitutive activity of these GPCRs and suggested this 
system for the screening of ligands. According to these authors the hY4R indeed showed 
elevated basal activity as it changed the transmittance of incident light by cells without being 
stimulated. However, in literature this assay format is not widely used for GPCRs, probably 
due to the variability of these cells (Suska et al., 2008) giving spurious results in conventional 
macroscopic evaluations. By contrast, the baculovirus/Sf9 expression system with its broad 
usability in binding and functional experiments has been successfully applied for plenty of G 
protein coupled receptors (Massotte, 2003). In view of the lack of potent and selective Y4 
antagonists we were aiming at a screening system for ligands, especially antagonists, at the 
hY4R. One potent and selective Y4 receptor agonist reported lately (Balasubramaniam et al., 
2006) has been identified in a radioimmuno cAMP assay and probed in feeding studies on 
mice after i. p. application. Since no potent antagonists are available, knockout animals 
lacking the Y4 receptor gene were the negative control and seem to be broadly in use 
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(Wultsch et al., 2006; Painsipp et al., 2008; Tasan et al., 2009). Thus, the development of 
reliable small molecule receptor ligands is still a challenging task and would greatly facilitate 
and accelerate investigations and drug discovery. For this purpose reliable functional assays 
are needed. 
 
6.2 Materials and Methods 
6.2.1 Preparation of SF-hY4R-His6 construct by overlap extension PCR 
Overlap extension PCR was essentially performed as described in section 5.2.1. However, for 
PCR 1b and PCR 2 different DNA polymerases and cycling conditions were applied. 
The PCR 1a was accomplished as described for the hY2R (section 5.2.1.1). 
In PCR 1b, pcDNA3-hY4, prepared by R. Ziemek (2006) was used as template. The hY4 
nucleotide sequence corresponds to GenBank accession no. U35232 published by Bard et al. 
(1995). Again, the receptor sequence was extended N-terminally by a part of the FLAG 
sequence and C-terminally by a hexahistidine tag, followed by the shifted stop codon and the 
XbaI restriction site. These modifications were introduced via the following primer pairs 
(MWG) used at a final concentration of 0.5 µM each. 
 
FLAG-hY4R-sense 5’- AAG GAC GAT GAT GAC GCC ATG AAC ACC TCT 
CAC CTC CTG -3’  
6His-hY4-as 5’- GG TCC TCT AGA TTA GTG ATG GTG ATG ATG GTG 
AAT GGG ATT GGA CCT GCC -3’ 
 
Reaction mixtures were prepared to a volume of 100 µl containing 5 U of PfuTurbo® DNA 
Polymerase (Stratagene, La Jolla, CA) with 10 µl of 10× Cloned Pfu DNA Polymerase 
Reaction buffer (Stratagene), MgSO4 (3.5 mM), dNTPs 50 µM each, 100 ng of template 
DNA, primers 0.5 µM each and DMSO 10 %. Cycling conditions were as follows:  
(1) initial denaturation  95 °C, 5 min   
(2) denaturation  95 °C, 1 min 
(3) annealing  65 °C, 2 min 
(4) extension  72 °C, 1.5 min 
(5) final extension  72 °C, 10 min 
(6) hold      4 °C   
Steps (2) to (4) were repeated 24 times. 
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10 µl of PCR 1b product were analyzed by agarose gel electrophoresis. The expected band 
was found at 1175 bps (Fig. 6.1). 
PCR 2 was carried out by analogy with PCR 1b using purified products of PCR 1a and PCR 
1b (2 µl each) as template and the sense pGEM and 6His-hY4-as primers (Fig. 6.2).  
After purification the PCR 2 product was subcloned into a pGEM-3Z and a pVL1392 plasmid 
as described for the hY2R in sections 5.2.2. and 5.2.3. The sequence of the construct SF-
hY4R-His6 was verified and one conservative mutation A66G (counted from the ATG of the 
receptor) was found.  
 
 
All subsequent steps including the GTPase assays were conducted as already described for the 
hY2R.  
 
 
 
 
 
 
 
 
 
Fig. 6.2: Agarose (1.5 %) gel 
electrophoresis of PCR 2 product; 
Sizes of DNA bands are indicated in 
bps.
500 
1500 
1000 
1436 
Fig. 6.1: Agarose (1.5 %) gel 
electrophoresis of PCR 1b product.; 
Sizes of DNA bands are indicated in 
bps. 
500 
1500 
1000 1175 
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6.2.2 Y4 receptor ligands 
The peptides hPP, K4-hPP, BW1911U90, rPP, pNPY, pPYY were kindly provided by Prof. 
Dr. C. Cabrele, (Ruhr-University of Bochum, Germany). GW1229 (also designated 
GR231118 or 1229U91) was a gift from Dr. J. Daniels, Glaxo Wellcome Inc., USA. The 
compounds AK 49, AK 377 and AK 472 were synthesized by A. Kraus  and the compounds 
PI 284, PI 317 and PI 330 were prepared by P. Igel (both from University of Regensburg, 
Germany). 
 
Table 6.1: Compounds tested at the hY4R 
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AK 472 
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6.3 Results and Discussion 
6.3.1 Immunoblot analysis of membranes 
6.3.1.1 Protein expression in membrane batch 
By analogy with the hY2R, a batch comprising a set of 16 membranes with different 
combinations of the hY4R with G proteins and RGS proteins was prepared as summarized in 
Table 6.2. 
 
Table 6.2: Overview of the set of membranes generated for the hY4R 
Membrane 
preparation Receptor Gα Gβγ RGS protein Protein [µg/ml] 
1644 SF-hY4-His6 Gαi2 Gβ1γ2 - 276 
1645 SF-hY4-His6 Gαi2 Gβ1γ2 RGS 4 1316 
1646 SF-hY4-His6 Gαi2 Gβ1γ2 GAIP 1232 
1647 SF-hY4-His6 Gαi1 Gβ1γ2 - 1286 
1648 SF-hY4-His6 Gαi1 Gβ1γ2 RGS 4 1612 
1649 SF-hY4-His6 Gαi1 Gβ1γ2 GAIP 1349 
1650 SF-hY4-His6 Gαi3 Gβ1γ2 - 1396 
1651 SF-hY4-His6 Gαi3 Gβ1γ2 RGS 4 1299 
1652 SF-hY4-His6 Gαi3 Gβ1γ2 GAIP 1344 
1653 SF-hY4-His6 Gαo1 Gβ1γ2 - 1539 
1654 SF-hY4-His6 Gαo1 Gβ1γ2 RGS 4 1499 
1655 SF-hY4-His6 Gαo1 Gβ1γ2 GAIP 1279 
1656 SF-hY4-His6 - - - 1076 
1657 - Gαi2 Gβ1γ2 - 1039 
1658 SF-hY4-His6 - - RGS 4 1379 
1659 SF-hY4-His6 - -  GAIP 1502 
 
After the preparation of membranes as described in section 5.2.6, 10 µg of samples were 
loaded onto 12 % SDS gels each, and blotted after electrophoresis onto nitrocellulose 
membranes, which were then reacted with antibodies as indicated in Fig. 6.3. Bands were 
found at molecular weights expected for each protein: Gα-subunits at 43 kDa, Gβ-subunits at 
36 kDa and RGS4 and GAIP at somewhat higher molecular weights than expected at 29 and 
31 kDa, respectively. Dimers and oligomers were found for the GAIP at 64 kDa and higher 
(Fig. 6.3 E). Protein expression levels were approximately the same in all membranes, except 
for the Gαi1-subunit, which showed weaker bands than the other Gα-subunits (Fig 6.3 B). 
Gαi2 in the control membrane (1657) showed a very pronounced band at 43 kDa giving 
account of the fact that in this case the cells had been infected with only two baculoviruses 
(encoding for Gαi2 and the dimer Gβ1γ2) instead of up to four. The FLAG-tagged hY4 receptor 
was expressed at approximately the same level in all membranes. Somewhat divergent band 
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intensities could be due to the determination of protein concentration performed only in single 
measurements. The receptor molecular weight found by immunoblot analysis was 45 kDa, 
which corresponds to the unglycosylated protein. However, the hY4R is a glycoprotein with 
four potential N-glycosylation sites, with glycosylation acconting for up to 20 kDa. 
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6.3.1.2 Quantitative immunoblot analysis 
To assess the receptor and G protein expression level of membranes, quantitative immunoblot 
analyses were performed. A high G protein/GPCR ratio ensures that the signal transduction of 
the hY4R is not compromised by limited availability of G proteins (Kenakin, 1997). 
Therefore, membranes, expressing hY4R + Gαi2 + RGS4 and hY4R + Gαo1 + RGS4 (always 
along with Gβ1γ2), were subjected to quantification of GPCR and G protein expression by 
immunoblot analysis (Fig. 6.4 and 6.5). With 1.4 and 1.8 pmol/mg the hY4R is expressed at 
comparable levels in all membrane preparations. Gαi2 amounted to ≈300 pmol/mg, while Gαo1 
is present at ≈150 pmol/mg, so the GPCR/Gα results in a ratio of ≈ 1:200 and ≈ 1:80, 
respectively (Table 6.3). 
 
 
E 
Fig. 6.3: Immunological detection of recombinant proteins expressed in Sf9 insect cells; 10 µg of protein 
from each membrane of the batch (1644-1659) were loaded on each lane. Numbers of membranes are 
shortened to the last two digits. Bands were detected with the following antibodies: (A) anti-FLAG, (B) anti-
Gαcommon, (C) anti-Gβcommon, (D) anti-RGS4 and (E) anti-GAIP. Figures on the left side of the blots designate 
masses of marker proteins in kDa. 
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Fig. 6.5: Quantitative immunoblot analysis of two membranes (1654 and 1765) expressing the hY4R + Gαo1 
+ Gβ1γ2 + RGS4 with the anti-FLAG (M1) and the anti Gαo antibody; A dilution of a reference membrane, 
expressing 7.5 pmol/mg hβ2AR and defined amounts of purified Gαo2 were used to estimate receptor and 
G protein expression levels. Figures on the bottom of each lane indicate the amount of membrane protein in 
µg or purified protein in fmol (Gαo2) loaded onto the gel. 
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Fig. 6.4: Quantitative immunoblot analysis of two membranes (1645 and 1763) expressing the hY4R + Gαi2 
+ Gβ1γ2 + RGS4 with the anti-FLAG (M1) and the anti Gαi1/2 antibody; A dilution of a reference membrane 
with the expression of 7.5 pmol/mg hβ2AR and defined amounts of purified Gαi2 were used to estimate 
receptor and G protein expression levels. The figures on the bottom of each lane indicate the amount of 
membrane protein in µg or purified protein in fmol (Gαi2) loaded onto the gel. 
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Table 6.3: Expression levels and ratios of proteins in Sf9 membranes 
Parameter hY4R + Gαi2 + RGS4 hY4R + Gαo1 + RGS4 
hY4R expression level 
[pmol/mg] 
1.4 ± 0.51 (n=5) 1.8 ± 1.12 (n=3) 
Gα expression level 
[pmol/mg] 
293 ± 1383 (n=3) 146 ± 422 (n=1) 
hY4R/Gα ratio 1 : 205 1 : 81 
All membranes contained proteins as indicated along with Gβ1γ2. 1determined with 3 different membrane 
preparations; 2determined with one membrane preparation; 3determined with 2 different membrane preparations. 
 
 
This is in good agreement with ratios determined for other Gi/o coupled receptors in Sf9 
membranes, for example the human histamine H3 receptor (Schnell et al., 2010), the human 
histamine H4 receptor (Schneider et al., 2009) or the human cannabinoid receptors CB1 and 
CB2 (Nickl et al., 2008). 
 
 
6.3.1.3 Effect of N-glycosylation on the structure and the expression level of the hY4R 
Defective N-glycosylation of GPCRs can affect receptor function, as shown, e.g., for the 
human formyl peptide receptor FPR (Wenzel-Seifert and Seifert, 2003), as well as receptor 
expression. For example, the expression level of non glycosylated hY1R, which possesses 
four potential extracellular N-glycosylation sites (like the hY4R), suffered a dramatic loss in 
the methylotrophic yeast Pichia pastoris compared to the glycosylated protein (Yurugi-
Kobayashi et al., 2009). Therefore, structural and functional (see section 6.3.4) analysis of 
glycosylated and non glycosylated hY4R have been performed via immunoblot and 
steady-state GTPase assays. 
When expressed in CHO cells, Voisin et al (Voisin et al., 2000) found a molecular weight for 
the hY4R of ≈60 kDa, which was reduced to ≈43 kDa after incubation with PNGase F, a N-
glycanase, and the rhesus Y4R had a size of ≈80 kDa expressed in HEK293 cells (Berglund et 
al., 2003a). By contrast, immunoblot analysis of membranes from Sf9 cells revealed a 
molecular weight of ≈45 kDa for the glycosylated (see also section 6.3.1.1) and of ≈36 kDa 
for the non glycosylated receptor, when the cells were cultured in the presence of 10 µg/ml 
tunicamycin (Fig. 6.6). Several explanations can be given for this discrepancy: for example 
Fabre et al. (1993) reported on diverse molecular weights for the VIP receptor, when prepared 
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from different tissues, and Sf9 cells are known to have very simple glycosylation patterns 
compared to mammalian cells (Grünewald et al., 1996; Massotte, 2003). In addition, several 
GPCRs, expressed in Sf9, cells have been found to migrate atypically in SDS-polyacrylamide 
gels such the dopamine D2S receptor (Grünewald et al., 1996), a mutant of the formyl peptide 
receptor (FPR-C126W) (Seifert and Wenzel-Seifert, 2001) or the guinea pig histamine H1 
receptor (Seifert et al., 2003). Thus, the differing molecular weights of the hY4R from those 
reported in literature are presumably due to both, differential N-glycosylation in Sf9 cells, and 
abnormal protein migration in SDS gels. Tunicamycin treatment decreased the molecular 
weight of the hY4R by about 9 kDa, which is in agreement with four potential N-
glycosylation sites. However, this reduction in weight is quite small, when compared to the 
results of the aforementioned studies. Regarding the protein expression level, a moderate 
decrease from ≈1.7 to ≈1.3 pmol/mg was found. 
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Fig. 6.6: Quantitative immunoblot analysis of 
two membranes, expressing the hY4R from 
tunicamycin treated (lanes marked by an 
arrow) and untreated cells, with the anti-
FLAG (M1) antibody; A dilution of a 
reference membrane (7.5 pmol/mg hβ2AR) 
was used to estimate the expression level of 
the hY4 receptor. Figures on the bottom of 
each lane indicate the amount of protein in 
µg loaded onto the gel. Expression levels 
were ≈1.7 pmol/mg and ≈1.3 pmol/mg for the 
glycosylated and the non glycosylated hY4R, 
respectively. 
Anti-FLAG (M1) 
1803 1804 
 Steady-state GTPase assay for the NPY Y4 receptor  97 
6.3.2 Coupling efficiency of the hY4R to Gαi/o proteins 
As described for the hY2R in section 5.3.2, the coupling efficiency of the hY4R was 
determined, using hPP as ligand. Fig. 6.7 shows the results as basal and stimulated GTPase 
activity in A and as relative to basal GTPase activity in B.  
 
 
Fig. 6.7: Comparison of the coupling efficiency of hY4R to Gαi/o proteins in the presence and absence of 
RGS4 or GAIP; The human Y4R was co-expressed with Gαi1, Gαi2, Gαi3 and Gαo1, each with Gβ1γ2 and with 
or without RGS4 or GAIP, respectively. Control membranes contained hY4R alone, hY4R in combination 
with RGS4 or GAIP and Gαi2 + Gβ1γ2. (A) Absolute GTPase activities under control conditions (open bars, 
basal) and upon stimulation with 100 nM hPP (black bars); (B) GTPase activities relative to basal expressed 
in percent; The data are means ± S.E.M. of at least 3 independent experiments performed in duplicate with 
one membrane batch prepared on one day. 
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Although G protein coupling of the hY4R has less been described in literature, reports are 
limited to the inhibition of forskolin stimulated cAMP formation via Gi/o proteins in 
transfected HEK293 cells (Dautzenberg et al., 2005) and inhibition of forskolin stimulated 
cAMP formation via Gi/o proteins and calcium mobilization in hY4 transfected LMTK- cells 
(Bard et al., 1995). Recently, Misra et al. (2004) co-expressed Y1R, Y2R, and Y4R in smooth 
muscle cells and found that all three receptors preferentially coupled to Gαi2, while Y2R and 
Y4R additionally activated Gαq.  
Our results (Fig. 6.7) show that the hY4R couples with comparable efficiency to all Gαi 
proteins and also to Gαo, although to a somewhat lesser extent. Endogenous G proteins of Sf9 
cells are activated only poorly by hY4R. Both RGS4 and GAIP enhance signaling 
considerably regarding mammalian and endogenous insect cell G proteins. The combinations 
hY4R + Gαi2 + RGS4 and hY4R + Gαo + RGS4 always co-expressed with Gβ1γ2 showed high 
signal-to-noise ratios, allowing the investigation of constitutive receptor activity, the 
pharmacological characterisation of ligands being full/partial agonists, neutral antagonists or 
inverse agonists and thus providing a well suited system for ligand screening.  
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6.3.3 Effects of monovalent salts on the GTPase activity  
By analogy with section 5.3.3, the hY4R has been studied with respect to its sensitivity to 
monovalent salts in the hY4R + Gαi2 + Gβ1γ2 + RGS4 Sf9 expression system (Fig. 6.8).  
NaCl decreased basal and stimulated GTPase activity (Fig. 6.8 A, D, G), which reveals a 
moderate constitutive activity of the hY4R, while LiCl and KCl showed much less effect. This 
is in accordance with elevated hY4R activity observed by Chen et al. when the receptor was 
expressed in melanophores (Chen et al., 2000). The efficacy of hPP was also affected by 
anions in the same range order of potency, Cl- < Br- < I-, as has been seen at the hY2R. Lately, 
Lindner et al. (2008) reported on ligand-receptor interactions for the NPY receptor family at 
the molecular level. The authors postulated two ionic interaction sites for pNPY at the hY2R 
compared to only one for hPP at the hY4R. This would mean that the hY2R binds its ligand 
tighter than the hY4R, thus being less sensitive to interferences by monovalent salts. 
 
Fig. 6.8: Basal and ligand-stimulated GTPase activity depending on the concentration of various 
monovalent salts as indicated on the abscissa; High-affinity GTPase activity was determined with a Sf9 
membrane expressing hY4R + Gαi2 + Gβ1γ2 + RGS4 under control conditions (○) and upon stimulation with 
100 nM hPP (□). Data are means ± S.E.M. of one representative experiment performed in duplicate. 
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The effect of NaCl on hY4R was studied also in combination with mammalian Gαi1, Gαi3, Gαo 
and with endogenous Sf9 insect cell proteins (always along with RGS4). No differences in 
concentration-response curves were found (Fig. 6.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.9: Basal and stimulated GTPase activity depending on the concentration of NaCl; High-affinity 
GTPase activity was determined with membranes expressing the hY4R in combination with different Gα-
subunits and RGS4 as indicated in titles above graph panels (always along with Gβ1γ2). Data are means ± 
S.E.M. of one representative experiment performed in duplicate. 
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6.3.4 Effect of N-glycosylation on receptor function 
According to immunoblot analysis (section 6.3.1.3) inhibition of N-glycosylation by 
tunicamycin causes a drop of ≈9 kDa of the receptor mass and a ≈0.5 pmol/mg decrease in 
receptor expression level. As revealed by the steady-state GTPase assay, the non-glycosylated 
hY4R loses its function and can no longer be stimulated with hPP (Fig. 6.10). This highlights 
the necessity of N-glycosylation for the hY4R. 
 
 
 
 
6.3.5 Evaluation of the hY4R Sf9 expression systems 
To investigate G protein specific effects on ligand potency, as described e.g. for the β2-AR 
(Wenzel-Seifert and Seifert, 2000), experiments for the construction of hPP concentration-
response curves and the calculation of hPP potency at membranes combining the GPCR and 
different Gα-subunits in the presence and absence of RGS4 were run (Fig. 6.11 and Table 
6.4).  
The shapes of the concentration-response curves are similar with all membranes used. The 
hPP potencies are in good agreement. Whether the EC50 values from hY4R + Gαi1 + RGS4 
and hY4R + Gαi3 + RGS4 (always co-expressed with Gβ1γ2) are significantly different from 
those obtained with other membranes, has to be evaluated in further experiments. 
Fig. 6.10: Concentration-response curves of 
hPP at hY4R, Gαi2, Gβ1γ2 and RGS4 expressing 
membranes from Sf9 cells grown in the 
presence (■) and absence (□) of tunicamycin; 
Data are means ± S.E.M. from a representative 
experiment performed in duplicate. 
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Fig. 6.11: Concentration-response curves of hPP at different co-expression systems (always along with Gβ1γ2  
except in I) as indicated on top of each graph; Curves were constructed from data in means ± S.E.M from one 
experiment each performed in duplicate or triplicate. NaCl was present in some experiments at a con-
centration of 50 mM (B, D, H). 
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Table 6.4: EC50 values of hPP, determined with different co-expression systems 
Membranes contained proteins as indicated in the head row of the table always along with Gβ1γ2 except for the 
last column. Data are means ± S.E.M. or single values from experiments performed in duplicate or triplicate. 
1n=1, 2n=2, 3EC50 determined in the presence of 50 mM NaCl 
 
 
To further validate the steady-state GTPase assay as a sensitive and reliable test system for 
hY4R ligands, the two membranes that yielded best signal-to-noise ratios (hY4R + Gαi2 + 
RGS4 and hY4R + Gαo1 + RGS4, always co-expressed with Gβ1γ2), were characterized 
pharmacologically with hY4R selective peptidergic ligands. 
Due to the sensitivity of the hY4R to sodium ions, experiments with hPP and GW1229 were 
performed in the presence of 50 mM NaCl and under control conditions. Representative 
curves are shown in Fig. 6.12. There is a noteworthy decrease in basal GTPase activity and 
maximal response, and the EC50 value increases significantly (p < 0.05) for hPP (from 11.0 ± 
3.6 nM to 28.3 ± 5.3 nM in the presence of 50 mM NaCl) with Gαi2. However, at the hY4R + 
Gαo1 + RGS4 the EC50 value of hPP remains unchanged with 17.9 ± 1.4 nM (control) and 
14.3 ± 3.6 nM in the presence of 50 mM NaCl. Regarding GW1229, there is a significant (p < 
0.001) eightfold increase in EC50 from 0.55 ± 0.15 nM to 4.6 ± 0.2 nM in the presence of 50 
mM NaCl at the membrane expressing hY4R + Gαi2 + RGS4. Likewise at the hY4R + Gαo1 + 
RGS4 the potency drops significantly (p < 0.05) by a factor of approximately five from 1.0 ± 
0.3 nM to 5.2 ± 1.2 nM in the presence of 50 mM NaCl. These findings are in accordance 
with reported KI values for hPP and GW1229 at rY4R differing in the presence and absence of 
NaCl (145 mM) (Parker et al., 2002). 
Intriguingly, the applied salt concentration raised the intrinsic activity of GW1229 from 82 % 
to approximately 100 % at both membranes. GW1229 has been reported both as a partial 
(Berglund et al., 2003b; Ziemek et al., 2007) and a full agonist (Parker et al., 1998; Berglund 
et al., 2003a).  
The ratio of stimulated (3 µM hPP) to basal GTPase activity was improved in the presence of 
50 mM NaCl by a factor of 1.4 with Gαi2 and 1.2 with Gαo1, respectively (Table 6.5). 
 hY4R + Gαi1 + 
RGS4 
Gαi2 Gαi2 + 
RGS4 
Gαi3 + 
RGS4 
Gαo1 Gαo1 + 
RGS4 
RGS4 
EC50 [nM] 42.21 - 11.0 ± 3.6 32.51 10.51 17.9 ± 1.4 16.5 ± 3.32
EC50 [nM]3 - 16.41 28.3 ± 5.3 - - 14.3 ± 3.6 - 
104 Chapter 6 
 
 
Table 6.5: Signal-to-noise ratios determined with ligands at two different co-expression 
systems in the presence and absence of NaCl 
 Signal-to-noise ratios at membranes: 
Ligand hY4R + Gαi2 + RGS4 hY4R + Gαo1 + RGS4 
hPP 1.90 ± 0.07 1.63 ± 0.07 
+ NaCl (50 mM) 2.37 ± 0.08** 2.11 ± 0.02* 
GW1229 1.70 ± 0.05 1.64 ± 0.05 
+ NaCl (50 mM) 2.26 ± 0.07*** 2.03 ± 0.04*** 
Signal-to-noise ratios were determined by dividing maximum (at hPP 3 µM or GW1229 100 nM) by basal 
GTPase activities. Membranes contained proteins as indicated always along with Gβ1γ2. Data are means ± 
S.E.M. from at least three (n ≥ 3) independent experiments performed in duplicate. Ratios were compared in the 
unpaired two-tailed t test with a confidence interval of 95 % (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Additional peptides were tested in the steady-state GTPase assay at both membranes for the 
hY4R system (Fig. 6.13). Generally, the pharmacological data were in the same range as 
known from literature (Dautzenberg et al., 2005; Ziemek, 2006). 
BW1911U90, a moderately potent Y4R agonist, pancreatic polypeptide from the rat (rPP) and 
pNPY were significantly (p < 0.05) more potent at membranes expressing Gαo1. Surprisingly, 
BW1911U90 was 18 (with Gαi2), respectively 40 (with Gαo1) times more potent than reported 
Fig. 6.12: Concentration-response curves of hPP and GW1229 at different co-expression systems (always 
along with Gβ1γ2) as indicated on top of graphs; Curves were constructed from means ± S.E.M from one 
representative experiment performed in duplicate. NaCl was present in experiments at a concentration of 
50 mM as indicated in the legends. 
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in literature (Parker et al., 1998). K4-hPP was chosen because of its use as fluorescently 
labeled ligand at the hY4R in binding assays in our work group (Ziemek et al., 2007). The 
potencies correspond very well to the data determined by Ziemek (2006) in the aequorin 
assay. The reported EC50 values of the peptide pPYY range from ≈13 to ≈106 nM 
(Dautzenberg et al., 2005; Parker et al., 2005) or even up to ≈600 nM (hPYY) (Merten et al., 
2007) depending on the assay system applied. Pharmacological data are summarized in 
Table 6.6 (section 6.3). 
 
 
6.3.6 Screening of potential NPY Y4R ligands 
Due to a lack of potent non-peptidic antagonists for the hY4R, a small library of chemical 
compounds prepared in our work group was screened for activity and affinity to the hY4R in 
aequorin assays as well as in flow cytometric binding assays as described by Ziemek (2006) 
for a pre-selection in order to be applied in the newly established steady-state GTPase assay. 
First the substances were tested at a concentration of 100 µM for their inhibition of the Ca2+-
signal triggered by 100 nM hPP in the antagonist mode. Compounds were chosen that 
suppressed the hPP signal to a value of less than 30 %. Then, the agonist mode was applied to 
Fig. 6.13: Concentration-response curves of agonistic peptides at different co-expression systems (always 
along with Gβ1γ2) as indicated on top of graphs; Curves were constructed from means ± S.E.M from one 
representative experiment performed in duplicate.  
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select compounds that did not evoke a luminescence signal greater than 35 % of the hPP 
signal within the cells at 100 µM. Inhibition curves of the chosen potential Y4 antagonists 
have been recorded in the aequorin assay (Fig. 6.14). Curves were fitted and IC50 values were 
calculated with the GraphPad Prism 5.01 software. Finally some of these substances were 
tested in a flow cytometric binding assay for their ability to displace the fluorescently labeled 
Cy5-K4-hPP (3 nM). Curves were fitted and IC50 values were determined with the GraphPad 
Prism 5.01 software (Fig. 6.15). 
Though promising results were obtained from the aequorin assay (for pIC50 values see 
Fig. 6.15) with AK 377 and PI 284 being somewhat more potent than AK 49, which was 
described by Ziemek et al. (2007) as the first non-peptidic antagonist for the hY4R, the 
affinities of the substances were not higher than that of AK 49 (Fig. 6.15). 
 
 
The compounds were also investigated in the newly established steady-state GTPase assay for 
their inhibition of the hPP (50 nM) induced signal at membranes containing hY4R + Gαi2 + 
Fig. 6.15: Competition binding of non-
peptidergic ligands at CHO-hY4R-
Gαqi5-mtAEQ in the flow cytometric 
binding assay; Cy5-K4-hPP was 
present at 3 nM. (mean values ± 
S.E.M., from one representative 
experiment, n = 3); 
IC50 values were: 
AK 49: ≈32 µM 
AK 377: > 100 µM 
PI 284: > 100 µM 
Fig. 6.14: Inhibition curves of non-
peptidergic ligands at CHO-hY4R-
Gαqi5-mtAEQ in the aequorin assay; 
hPP was present at 100 nM (mean 
values ± S.E.M., from one experiment, 
n = 3). pIC50 ± S.E.M values were: 
AK 49   4.7 ± 0.1 (19.2 µM) 
AK 377   5.3 ± 0.1 (5.4 µM) 
AK 472   4.7 ± 0.1 (18.3 µM) 
PI 284   5.2 ± 0.1 (5.7 µM) 
PI 317   4.4 ± 0.1 (38.2 µM) 
PI 330   4.8 ± 0.1 (14.6 µM) 
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Gβ1γ2 + RGS4. Intriguingly, AK 49 had the poorest potency (> 500 µM), while the other 
substances showed IC50 values between 100 and 500 µM (Fig. 6.16 A). However, hPP 
stimulated GTPase activity was suppressed to values below basal (except for PI 317). Due to 
the very high concentrations used, presumably, receptor independent effects take place. 
Concentration-response curves of hPP in the absence and presence of PI 330 and PI 284 were 
recorded (Fig. 6.16 B). Potential negative effects of the solvent of the ligands were checked. 
However curves from experiments with and without 1 % DMSO were not different from each 
other. Determined pEC50 values for hPP in these experiments were somewhat higher than 
usual (7.25 ± 0.09 and 7.31 ± 0.07). As shown in Fig. 6.16 B PI 330 (30 and 50 µM) and PI 
284 (50 µM) both shifted the concentration-response curve of hPP to the right yielding pEC50 
values of 6.71 ± 0.09, 6.73 ± 0.08 and 6.82 ± 0.08, respectively. As the maximum signal was 
depressed by both substances by 15 – 25 %, PI 330 and PI 284 do not behave as typical 
competitive antagonists. 
 
Taken together, the promising results obtained with substances in the aequorin assay could 
not be reproduced with the steady-state GTPase assay. This is presumably due to receptor-
independent effects of the compounds as the affinities were not higher than in the case of 
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Fig. 6.16: Inhibition and concentration-response curves of potential non peptidergic ligands at membranes 
containing hY4R + Gαi2 + Gβ1γ2 + RGS4 in the steady-state GTPase assay; (A) Inhibition curves were 
recorded in the presence of 50 nM hPP, basal GTPase activity of non stimulated membranes is indicated as a 
dotted line. Means ± S.E.M from one representative experiment performed in duplicate. (B) Concentration-
response curves of hPP under control conditions, in the presence of 1% DMSO, 30, respectively 50 µM 
PI 330 and 50 µM PI 284. Means ± S.E.M from three independent experiments performed in duplicate. 
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AK 49 in the flow cytometric binding assay. Furthermore, as membranes are used for the 
GTPase assay, there is no physiological barrier for the substances to prevent their direct 
interaction with, e.g., G proteins at the very high concentrations (obvious from the dramatic 
drop of GTPase activity at concentrations > 100 µM). However, with the rightward-shift of 
curves by PI 330 and PI 284 two additional substances have been identified to further 
optimize binding and antagonism of ligands at the hY4R. 
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6.4 Summary and conclusions 
The functional reconstitution of the hY4R together with mammalian Gi/o proteins and RGS 
proteins in Sf9 cells was successful. Characterization of cell membranes containing the 
GPCR, Gi/o proteins and RGS proteins by immunoblotting revealed expression levels of 
proteins and GPCR/G protein ratios comparable to values from other GPCR co-expression 
systems reported in literature. Functional characterization of membranes in a steady-state 
GTPase assay showed that the hY4R couples with comparable efficiency to all mammalian 
Gi/o proteins applied. The sensitivity of the hY4R towards monovalent cations revealed its 
moderate constitutive activity, as the basal receptor activity dropped in the presence of 50 mM 
NaCl. Furthermore, N-glycosylation of the hY4R showed to be essential for receptor function. 
The co-expression systems hY4R + Gαi2 + RGS4 and hY4R + Gαo1 + RGS4 (always along 
with Gβ1γ2) were chosen to determine pharmacological parameters of peptidergic ligands (cf. 
Table 6.6), which were in good agreement with data reported in literature. Moreover, hY4R + 
Gαi2 + Gβ1γ2 + RGS4 has been successfully applied for ligand screening. 
 
Table 6.6: Pharmacological parameters of hY4R ligands determined in the steady-state 
GTPase assay 
Ligand hY4R + Gαi2+RGS4 hY4R + Gαo1+RGS4 
  EC50 [nM] Emax EC50 [nM] Emax 
hPP 11.0 ± 3.6 - 17.9 ± 1.4  - 
+ 50mM NaCl 28.3 ± 5.3+ - 14.3 ± 3.6  - 
GW1229 0.55 ± 0.15 0.82 ± 0.04 0.97 ± 0.3 0.82 ± 0.02 
+ 50mM NaCl 4.6 ± 0.2+++ 0.97 ± 0.03+ 5.2 ± 1.2+ 1.03 ± 0.01++ 
K4-hPP 143.0 ± 24.4 1.02 ± 0.06 76.7 ± 10.9 0.98 ± 0.06 
BW1911U90 8.9 ± 1.5 1.28 ± 0.03 4.2 ± 0.4* 1.09 ± 0.01** 
rPP 274. 8 ± 49.2 0.86 ± 0.03 127.4 ± 31.0* 0.97 ± 0.04 
pNPY 416.9 ± 42.0 0.56 ± 0.05 218.1 ± 39.4* 0.59 ± 0.08 
0.662 pPYY 400.2 ± 311.21 0.61 ± 0.041 84.92 
Mean values ± S.E.M. of at least three independent experiments (unless indicated otherwise) performed in 
duplicate; EC50 and Emax values were compared in the unpaired two-tailed Sudent´s t-test with a confidence 
interval of 95 %. (+experiments with the same ligand and the same membrane performed in the presence of 50 
mM NaCl in comparison with experiments performed under control conditions, *comparison of membranes 
expressing the hY4R + Gαi2 + RGS4 versus membranes, expressing the hY4R + Gαo1 + RGS4 (always along with 
Gβ1γ2), one symbol: p < 0.05, two symbols: p < 0.01, three symbols: p < 0.001), 1 n=2; 2 n=1.  
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Thus, the newly established steady-state GTPase assay together with the Sf9 insect cell 
expression system proved to be reliable and sensitive tools not only for ligand screening but 
also for investigations on the molecular level, for instance, regarding receptor glycosylation 
and G protein coupling. 
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7 Summary 
 
For the pharmacological characterization of GPCR ligands in addition to binding data, the 
determination of the quality of action, agonistic potency or antagonistic activity is a must. 
There are numerous methods to determine potency and efficacy of ligands at the GPCR of 
interest, each of which has its specific applications, advantages and disadvantages. Therefore, 
a maximum of information on a given GPCR is obtained by combining complementary 
approaches. This thesis aimed at the development of functional assays exploiting FRET-, 
bioluminescence- and radioactive techniques. 
The FRET-based cAMP biosensor Epac2-camps was expressed in SK-N-MC cells to 
establish an assay to identify potential Y1R ligands in High Throughput Screening. Thereby 
changes in CFP/YFP signal ratio due to altered intracellular cAMP levels in response to 
adenylyl cyclase stimulation with forskolin and inhibition via Y1R activation are measured. 
Spectra of SK-N-MC-Epac2-camps cells were recorded in suspension and background 
corrected. Upon treatment with forskolin and the PDE inhibitor IBMX, the CFP/YFP ratio, 
calculated from intensities of the maximum emission peaks, increased. According to theory, 
this is because the fluorophores move away from each other due to unfolding of the protein 
upon binding of cAMP. The initial results were irreproducible, presumably due to poor stable 
transfection efficiency and low Epac2-camps expression. Therefore the same experiment was 
conducted on single cells using a confocal microscope equipped with a Meta detector for 
spectrum acquisition. However, meaningful changes in ratios were not observed, although 
adequate cAMP formation in SK-N-MC cells was shown previously by conventional 
methods. Thus, further investigation of Epac2-camps was discontinued. 
HEC-1B-hY5 cells, stably expressing the hY5R were considered a suitable starting point to 
develop functional fluorescence- and bioluminescence-based Ca2+ assays. While only small 
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Ca2+ transients were measured in a flow cytometric assay upon stimulation with pNPY in 
these cells, a robust signal was elicited when the cells were expressing Gαqi5. This effect was 
receptor specific because it was inhibited by the Y5R antagonist CGP 71683A. The 
concentration response curve of pNPY revealed an EC50 comparable to values reported in 
literature. Since the expression of chimeric G protein declined over time, the parent cells were 
newly transfected with Gαqi5 and Gαqi9, respectively. All resulting transfectants showed only 
poor Ca2+ mobilization in flow cytometric and fluorimetric measurements, though high pNPY 
concentrations were used. In an additional approach, HEC-1B-hY5-Gαqi5/9 cells were 
transfected with mitochondrially targeted apoaequorin and tested for their ability to emit 
luminescence upon treatment with the non ionic detergent, triton-X-100. Signals were only 
obtained from cells expressing Gαqi9. The measured response was weak compared to that 
obtained with CHO cells, stably expressing hY2/4R, Gαqi5 and mtAEQ. Thus, an aequorin 
assay for the hY5R was not fully established. Nevertheless, optimization of the generation and 
selection of stable HEC-1B-hY5 transfectants might pave the way for versatile functional 
calcium assays. 
Finally, with the establishment of a steady-state GTPase assay a classical radioactive 
technique was applied. For this purpose, baculoviruses encoding the sequences of hY2R and 
hY4R were generated. Functional reconstitution of the receptors with different members of the 
Gi/o protein family and RGS proteins in Sf9 insect cells enabled the determination of coupling 
efficiencies to G proteins and the identification of the best co-expression systems to yield 
robust stimulation and high signal-to-noise ratios. Evaluation of membranes, expressing hY2R 
+ Gαi2 + Gβ1γ2, hY4R + Gαi2 + Gβ1γ2 + RGS4 and hY4R + Gαo1 + Gβ1γ2 + RGS4, was 
performed with peptidergic agonists and non-peptidic antagonists (Y2R) yielding pharmaco-
logical data in good agreement with values reported in literature. The hY4R stimulated 
GTPase activity proved to be sensitive to monovalent cations, indicating moderate con-
stitutive receptor activity. Interestingly, only the hY4R showed a pronounced decrease in 
molecular weight and a loss of function, when expressed in the presence of tunicamycin, 
which inhibits N-glycosylation. The hY2R was much less affected. Thus, with the steady-state 
GTPase assay a well characterized system and a very useful model to search for potent Y2 and 
Y4 antagonists and inverse agonists has been established. 
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